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The Sub-Saharan African region remains the most severely affected by the HIV/AIDS epidemic. At the 
end of 2011, The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated that about 5% of 
adults were living with the HIV in this region, accounting for 69% of the global HIV prevalence. Efforts 
to curb the epidemic are focused on managing HIV through prevention strategies, such as advocating 
the use of condoms or pre-exposure or post-exposure prophylactic treatment, and prolonging life 
through the use of antiretroviral (ARV) therapy. Drugs used in ARV therapy target different major steps 
of the HIV reproductive cycle. These are nucleoside and non-nucleoside reverse transcriptase 
inhibitors (NRTIs/NNRTIs); fusion/entry inhibitors; integrase inhibitors; and protease inhibitors (PIs). 
In South Africa PIs, specifically lopinavir (LPV) boosted with another PI, ritonavir (RTV) are used in 
second-line ARV regimens along with a backbone of 2 NRTIs. The use of ARVs is not without issues – 
patients often experience side-effects to the drugs such as nausea, diarrhoea, and lipodystrophy with 
LPV use, which may influence their adherence to treatment and eventually lead to treatment failure. 
Inter-individual variability exists in patients’ response to treatment despite the standard dose of 400 
mg/100 mg (LPV/RTV) that is given and this may be due to differences in transport or metabolism of 
the drug in the liver. High plasma drug levels (associated with side-effects or toxicity) may be a result 
of poor metabolism or conversely, low plasma drug levels (associated with failure to suppress the 
virus) may be a result of extensive metabolism of the drug. Proteins involved in the disposition of LPV 
include the drug metabolising enzymes, CYP3A4 and CYP3A5; the hepatic uptake transporter, 
OATP1B1; and the efflux transporter, MRP2. Variation in the genes encoding these proteins may 
influence their functioning and hence LPV disposition. The aim of the study was to identify significant 
single nucleotide polymorphisms (SNPs) in each gene; to genotype a cohort of HIV-infected patients 
from Malawi and South Africa to identify the frequency of those variants; and to correlate genotypes 
with LPV plasma levels and other clinical parameters. Blood was obtained from 86 HIV-infected 
participants on LPV treatment. Genotyping was performed using PCR-RFLP for CYP3A4*1B; CYP3A5*3; 
CYP3A5*6 and ABCC2 1249G>A; TaqMan genotyping assay for CYP3A4*22; and sequencing to identify 
variants within SLCO1B1 exon 5 and exon 6 to 7, including c.388A>G and c.521T>C. Thirty-two SNPs in 
four genes were identified in the study. LPV plasma levels of participants ranged from 0.0206 to 38.6 
µg/mL. An association with LPV pharmacogenetics was observed for CYP3A4*1B and SLCO1B1 
rs4149049A>G. No other association was found between the variants determined through PCR-RFLP 
genotyping and LPV plasma levels. Notably, CYP3A4*22 and SLCO1B1 c.521T>C, which are suggested 
to influence the disposition of LPV in other populations, were not observed in our cohort. This 
highlights the need for further pharmacogenetic studies in sub-Saharan Africa in order to optimise HIV 
treatment available.  
1 
1. Introduction
1.1 Epidemiology of HIV/AIDS
Since the first HIV cases were reported in the early 1980s, the prevalence of Human Immunodeficiency 
Virus (HIV)-infected individuals increased to approximately 35 million cases worldwide by the end of 
2013 [(1) Table 1.1]. Africa is the continent with the highest burden of the disease (Fig 1.1). HIV is 
classified into two types (HIV-1 and HIV-2) within which several subtypes have been described owing 
to the degree of genetic diversity present (2, 3). HIV-1 is the most prevalent type and is reported 
among infected patients in many regions of the world including Sub-Saharan Africa, the United States 
and Europe, whereas HIV-2 is prevalent in the West African region (2). For the remainder of this 
literature review, HIV-1 will be the focus and will be simply referred to as HIV. 
Table 1.1 Summary of the global figures for the HIV/AIDS Epidemic in 2013 
Number of people 
living with HIV 
People newly infected 
with HIV 
AIDS deaths Other 
Reference 
Total (million) 35.0 2.1 1.5 
Adults (million) 31.8 1.9 1.3 
Women (million) 16.0 0.38 N/A (1) 
Children (<15 years) (million) 3.2 0.24 0.19 
Table adapted from the World Health Organisation (WHO) Data and Statistics. Global summary of the HIV/AIDS 
epidemic (2013)(4)  




Figure 1.1 Prevalence of HIV in adults (15-49 years) in different regions of the world. Adapted with 
modification from WHO Global Health Observatory programme. Available at: 
http://www.who.int/gho/hiv/hiv_013.jpg?ua=1 
 
The sub-Saharan African region, which includes countries such as South Africa, Malawi and Zimbabwe, 
remains the most affected by the HIV/AIDS epidemic. At the end of 2011, UNAIDS estimated that 
approximately 5% of adults were living with the HIV in this region, accounting for 69% of the global 
HIV prevalence (5). In support of this, the World Health Organisation (WHO) reported in 2012 that 
71% of the worldwide HIV cases were found within the sub-saharan African region 
(http://www.who.int/gho/hiv/epidemic_status/cases_all_text/en/). The United Nations AIDS agency 
(5) reports that, although many challenges regarding the Acquired Immune Deficiency Syndrome 
(AIDS) epidemic still need to be addressed and overcome, there is an increase in encouraging news 
related to the global state of AIDS. For instance, at the end of 2012, a 34% decline in the number of 
newly infected people in the Sub-Saharan African region was reported (6), and the prevalence of HIV 
among young people (between 15 and 24) had decreased by 42% at the end of 2012 in Sub-Saharan 
Africa (7).  Although these declines highlight the progress made in efforts aimed at HIV prevention 
(will be discussed below), the high prevalence of individuals living with HIV still warrants improving 
HIV treatment strategies. 
 
This great burden of HIV warrants the continued promotion of research focusing on populations in 
this region, whereas currently much of the data reported is generated from studies carried out on 




1.2 Management of HIV/AIDS 
The WHO estimates that currently half of the people living with HIV worldwide are unaware of their 
HIV status (8). This poses a large problem as the delay in HIV testing as well as poor counselling services 
available in many low to middle income countries lead to a delayed assessment of antiretroviral 
therapy (ART) eligibility and late access to treatment. Thus, when these infected individuals eventually 
begin treatment they would have been severely immunocompromised, resulting in a poorer 
prognosis. Furthermore, time that HIV-infected individuals take unaware of their status, increases 
their likelihood of spreading the  virus (8). In order to improve HIV testing, the WHO has included in 
its consolidated guidelines, a discussion on self-testing and considerations for policy-makers (9). 
Although HIV self-testing is not a full-proof means of diagnosing one’s HIV-status and does not rule 
out the need for testing by clinicians, researchers hope that more people will be encouraged to test 
as it allows for privacy; autonomy and greater convenience for patients. The need for HIV-testing goes 
hand-in-hand with the need for adequate counselling services. The WHO recommends that HIV testing 
and counselling not only be available in clinical settings, but also in community settings to allow for 
greater access to these services. As part of managing HIV and in order to improve the quality of life of 
individuals infected with the virus, services for emotional support; nutritional advice; advice on family 
planning for those with HIV are added recommendations (8). 
 
1.2.1. Prevention 
In many cases where an individual is at a higher risk for contracting HIV, it is important to consider 
means of prevention. HIV prophylaxis aims to aid in the management of HIV by reducing the number 
of people in high-risk situations who will contract the virus and, thereby, lowering the incidence of 
people who become infected with HIV. As a tool for prevention of HIV contraction, condoms have 
proved to be an effective barrier to HIV transmission. Johnson et al. (10) reported that in South Africa, 
condom use seemed to have accounted for a bigger proportion of the  decrease in HIV incidence 
between 2000 and 2008. In South Africa, male circumcision has also been lauded as an effective means 
of reducing risk of acquiring HIV infections and is thought to be more cost-effective than ART in 
preventing HIV infections (11). 
 
ART as a means of HIV prevention was initially used for the prevention of mother to child transmission 
(reviewed by Mutevedzi et al.(11) however, currently ART is also used to prevent HIV transmissions in 
other populations. Populations that are reported to benefit from pre-exposure prophylaxis (PrEP) as 
a form of prevention through the daily use of antiretroviral (ARV) drugs include serodiscordant couples 
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(one partner is HIV-infected while the other is HIV-negative); high risk heterosexual couples; men and 
transgender women who have sex with men and  people who inject drugs (8, 12). Cohen et al. (12) 
reported that, for serodiscordant couples,  early initiation of ART (when CD4 count is between 350 
and 550 cells/mm³) in HIV-infected patients was more effective in preventing the transmission of HIV 
to the uninfected partner than delayed initiation of ART (CD4 count 200 to 250 cells/mm³). PrEP 
involves the use of tablets (Truvada, a combination of the ARV drugs emtricabine and  tenofovir 
disoproxil fumarate) or a mucosal microbicide (in the form of a topical gel) (13, 14). However, mucosal 
microbicides have not shown to be as effective as condom use and ART in preventing HIV transmission 
(15). The challenges with prophylactic treatment include non-adherence to the prophylactic 
treatment (16); development of ARV resistance due to prolonged use; and mucosal safety (11, 17).  
 
When an individual has already been exposed to HIV, post-exposure prophylaxis (PEP) is a means of 
preventing contraction of the virus. Within 72 hours of exposure to HIV, the individual is to be placed 
on a short-term ARV regimen for 28 days (8). PEP requires diligent use and as suggested by the WHO, 
ART is required for a certain period of time in order for it to be effective (18). Poor adherence to the 
various prevention strategies remains the greatest barrier to their efficacy (16, 18). 
 
1.2.2. Treatment 
None of the available ARV drugs are curative of HIV/AIDS, rather they merely act to prevent further 
infection of host cells by the virus. As there is no cure for HIV, the current goal of HIV treatment for 
those infected is maintaining viral suppression by achieving a viral load persistently below the level of 
detection (HIV RNA <20 to 75 copies/mL) and hence, improving immune function (19) . According to 
the updated AIDS Info guidelines (http://aidsinfo.nih.gov/guidelines) the CD4 count of HIV patients 
needs to be measured routinely and, for those on treatment, CD4 count is expected to increase by 
approximately 50 to 100 cells/mm³ yearly until steady state is reached (>500 cells/mm³; (8). In efforts 
to achieve the goals of treatment, combination ARV therapy (cART), has largely contributed towards 
decreased morbidity and mortality in HIV patients (5, 20).  
 
Highly Active Antiretroviral Therapy (HAART) involves the use of 2 or more ARV drugs (cART) in order 
to suppress HIV viral replication in infected patients and its efficacy was first reported in 1997 (21). 
Gulick et al. (21)  reported that the use of 3 ARV drugs: 2 nucleoside reverse transcriptase inhibitors 
(NRTIs), and 1 protease inhibitor (PI) in patients resulted in a greater decrease in HIV-RNA over 24 
weeks compared to patients who were taking 2 NRTIs or on single NRTI-drug regimens. Since then, 
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cART has become the standard form of HIV ART with different classes of ARVs being combined in each 
regimen as is discussed further below. 
 
The challenges with cART are often associated with high pill burden (which has recently been 
addressed by the new single pill containing combination of tenofovir (TDF), emtricitabine (FTC) and 
efavirenz (EFV) (22); drug-drug interactions (for example with drugs that are common substrates for 
major drug metabolising enzymes, such as cytochrome P450 which will be discussed later); adverse 
side effects; number of times per day that the drugs have to be taken and development of drug 
resistance. These factors reduce patient compliance in taking their medication, a form of poor 
adherence, which leads to reduced efficacy of treament and high likelihood of development of drug-
resistant virions.  
 
1.2.3. Co-morbid Diseases and Opportunistic Infections 
The management of HIV not only involves medical intervention through ARV drugs, but also includes 
managing other illnesses that may arise due to the prolonged life span of patients such as diabetes 
and cardiovascular disease (23). The immune compromising effects of HIV makes patients susceptible 
to other opportunistic infections including tuberculosis (TB), cryptoccocal meningitis and 
Pneumocystis carinii pneumonia (24, 25). The introduction and availaibilty of ART has led to a decrease 
in the incidence of opportunistic infections (25).  
 
1.3 Antiretroviral Therapy (ART) 
The U.S. Food and Drug administration has approved more than 30 ARV drugs as of December 2014, 
for the treatment of HIV (26, 27). Each of these drugs target a specific step of the HIV life cycle (Fig. 
1.2). The main steps in the HIV life cycle include: binding of the viral proteins to host cell co-receptors; 
fusion of the virus with the host cell; reverse transcription of viral RNA to DNA; integration of the viral 
DNA into the host genome; synthesis of viral proteins; and cleavage of precursor polypeptides by viral 
proteins to form mature, infectious virions [Fig. 1.2; (3, 26)]. Treatment of HIV involves the targeting 
of each of these steps in order to arrest the HIV replicative cycle and inhibit further infection of host 
cells. ARVs are divided into 5 classes (see Table 1.2), namely NRTIs; non-nucleoside reverse 
transcriptase inhibitors [NNRTIs; (28, 29)]; PIs (30); fusion inhibitors (31); entry inhibitors [e.g. CCR5 
co-receptor antagonists (32, 33)]; and HIV integrase strand transfer inhibitors (34). Fusion Inhibitors, 
Entry Inhibitors and HIV integrase strand transfer inhibitors are the newest classes of inhibitors. Each 





Figure 1.2 Replicative life cycle of HIV. Figure highlights targets for ARV action. Adapted without 





Table 1.2 Antiretroviral Drugs approved by the U.S. Food and Drug administration and 
recommended for use in the treatment of HIV in South Africa.  





analogous dNTPs as 
substrates for HIV 
reverse transcriptase 
enzyme. Incorporation 
of NRTI into the nascent 
viral DNA chain results 




stavudine (d4T)  
lamuvidine (3TC) 









Target an allosteric site 
near the active site of 
the enzyme and, 
thereby, induce 
conformational changes 








Protease Inhibitors (PIs) Inhibit the HIV protease 
enzyme preventing it 
from cleaving the gag 
and gag-pol precursor 
proteins, inhibiting the 












Fusion Inhibitors Disrupt interactions of 
the HR1 and HR2 
domains of the gp41 
protein of the virus, 
preventing the fusion of 
the viral envelope to 
the host cell membrane 
enfuvirtide (T-20) (36) 
Entry Inhibitors - CCR5 co-
receptor antagonist 
Block interactions of 
the viral proteins and 
the CCR5 co-receptor of 
the host cell to inhibit 
fusion of the virus to 
the host cell 
maraviroc (MVC) (36) 
Integrase Strand Transfer 
Inhibitors 
Act on the HIV 
integrase enzyme and 
the viral DNA ends to 
prevent the viral 
genome from being 







1.3.1. ARV treatment regimens 
According to the 2013 WHO guidelines (8), ART should be initiated in HIV-infected adults in WHO 
clinical stage 3 or 4 when an individual’s CD4 count is below 350 cells/mm³; or below 500 cells/mm³ 
for HIV-infected individuals, regardless of WHO clinical stage. Exceptions are in the cases of patients 
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co-infected with HIV and TB; with HIV and hepatitis B virus or partners with HIV in serodiscordant 
couples – these patients are initiated on ARV regardless of their WHO clinical stage or CD4 count (38, 
39). WHO clinical stage 3 or 4 is defined as severe or advanced HIV clinical disease characterised by 
symptoms such as weight loss of more than 10% of body weight; unexplained chronic diarrhoea, 
anaemia, persistent fever; pulmonary TB (WHO 2010 Interim WHO Clinical Staging of HIV/AIDS and 
HIV/AIDS case definitions for surveillance). 
 
1.3.1.1 First-line ART 
When patients begin ARV treatment (ART), they are first placed on a first-line regimen consisting of 
two NRTIs plus a NNRTI. The preferred fixed-dose combination recommended by the WHO includes 
TDF; lamivudine (3TC) or FTC; and EFV (i.e. TDF+3TC/FTC+EFV). The use of stavudine (d4T) in ART has 
been discontinued due to the toxicities associated with the drug including peripheral neuropathy, 
lactic acidosis and severe hepatomegaly (8, 40). d4T treatment in HIV/AIDS patients has been 
suggested to result in mitochondrial depletion, with patients showing a lower mitochondrial DNA to 
nuclear DNA ratio (mtDNA/nDNA) compared to healthy controls (41). The WHO suggests that patients 
still on d4T be switched to zidovudine (AZT). The preferred first-line regimen according the WHO as of 
2013 is once daily TDF + 3TC (or FTC) + EFV and alternative regimens are (AZT + 3TC + EFV; AZT + 3TC 
+ NVP; and TDF + 3TC (or FTC) + NVP) in ART-naïve patients (8). Pregnant women and women who are 
breastfeeding may experience adverse effects with NVP treatment, such as hepatotoxicity and severe 
skin rashes and regimens with EFV may be used rather than NVP.  
 
In high income countries, viral load is routinely measured in order to monitor treatment efficacy, 
whereas in low to middle income countries CD4 count and clinical prognosis are often used to monitor 
treatment as these measures are more accessible than viral load testing (42). At treatment failure, 
genotypic resistance tests are useful in determining whether patients should continue on the current 
regimen (if showing no resistance) or whether they should switch to more expensive second-line 
treatment. Unfortunately, these tests are often not easily accessible in low to middle income 
countries, and thus some patients may be switched to second-line treatment unnecessarily (43). 
Therefore, as suggested by Levison et al. (43) genotypic resistance testing may be cost effective in 
South Africa through identifying patients with virologic failure who actually have the wild-type virus, 




1.3.1.2 Second-line ART 
In order to assess how patients are faring on the treatment, viral load is measured or, if viral load is 
not available, CD4 count is measured (8). Measures of treatment failure are virologic, immunological 
and clinical. Virologic failure entails a viral load which exceeds 1000 copies/mL after 2 successive 
measurements (with a 3 month interval); immunological failure is noted when a patient presents with 
a low CD4+ cell count (<50 cells/mm³); whilst clinical failure is noted when patients reach WHO clinical 
stage 4 (8). Patients presenting with first-line treatment failure are switched to a second-line ARV 
regimen which consists of a boosted PI; such as LPV/r (LPV boosted with RTV); plus a NRTI backbone 
as recommended by the WHO (8). The incidence of switching from first-line ART to second-line ART is 
predicted to be low in resource-limited countries (44) which may be partly due to the poor sensitivity 
of using immunological criteria to measure treatment failure rather than viral load. Delayed switching 
of treatment may influence patient response: morbidity and mortality.  
 
In 23 resource-limited countries (Burkina Faso, Burundi, Cambodia, Cameroon, Côte d’Ivoire, Ethiopia, 
Guatemala, Haiti, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Russian Federation, 
Rwanda, Swaziland, Tanzania, Thailand, Uganda, Zambia, and Zimbabwe) 4% of HAART patients (which 
translates into 34 040 individuals) were predicted to be on second-line ART in 2007 (42, 45) however 
only 25% of those patients on second-line therapy were on regimens recommended by the WHO: 
including: ABC+ddI+LPV/r (24%) and TDF+ddI+LPV/r (1%). In 2012, the number of people in low-to-
middle income countries on second-line therapy was estimated to be 500 000 (46). Renaud-Théry et 
al. (45) suggest that the use of second-line therapy may be more complicated than that of first-line 
therapy as the choice of second-line treatment is dependent on drugs used in first-line therapy; and 
the cost of second-line drugs may affect the ability of resource-limited countries to adhere to 
recommended drugs. For patients with no prior experience to PIs who are placed onto a second-line 
regimen with a boosted PI (such as LPV/r) the greatest predictor of viral suppression is adherence to 
treatment (47). In a study by Murphy et al. (47), adherence to treatment was the main predictor of 
viral suppression over a 12 month period while poor adherence could  partially explain the reported 
treatment failure among 25% of the patients. This observation was also supported by a report on HIV 
infected adults and children who were followed up for 20 months while on second-line ART (48); and 
then later by Court et al. (46) who report an association between poor adherence and predicted 
virologic failure on second-line ART and, conversely, between adherence and virologic suppression. 
Court et al. (46) used the pharmacy refill tool which measures short-term adherence to treatment. 
Adherence may be the greatest predictor of viral suppression in patients on second-line ART with PIs 
(46, 49), however, adherence is not the only factor; there are other possible reasons for the failure of 
second-line treatment to improve patient treatment outcomes. As with genotypic resistance that is 
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known to lead to first-line treatment failure, resistance to PIs could possibly play a role in second-line 
treatment failure. This study evaluates the pharmacogenetic component that is associated with 
response to LPV. 
 
1.3.1.3 Protease Inhibitors and their mechanism of action 
Through binding to the viral protease, PIs prevent the cleavage of the gag and gag-pol precursors into 
smaller viral proteins, a process essential for the formation of mature virions (30, 50). As immature 
viral particles are released from the infected host cell, further infection of host cells by newly 
synthesised virions is prevented (51). There are several PIs (listed in Table 1.2 above) which include 
RTV and LPV. Figure 1.3 below is a schematic showing how PIs form a complex with the HIV viral 




Figure 1.3 Various Protease Inhibitors and the crystal structure of HIV viral protease, complexed 
with the PI atazanivir. The arrow points to the site of the protease inhibitor within HIV protease. 




The current regimens that include LPV are as follows: AZT+3TC + LPV/r for patients in whom TDF was 
used in first-line treatment or; TDF+3TC (or FTC) + LPV/r for patients in whom AZT was used in first-
line treatment (8). The recommended alternative PI to LPV/r used in second-line therapy is atazanavir 
(ATV) which is also boosted with RTV. Other boosted PIs (darunavir, saquinavir (SQV/r); indinavir 
(IDV/r); fosamprenavir (FPV/r) are not available as fixed dose combinations and are associated with 
higher pill-burdens and with severe side effects. In resource-limited countries, LPV/r is currently the 
preferred option for second-line ART (47). However, due to the adverse side effects associated with 
LPV/r use, research aimed at making LPV/r more tolerable in patients or reducing the cost of newer 
PIs such as DRV is warranted, especially in developing nations (47, 53). Failure in second-line ART leads 
to recommending patients for third-line treatment, which is even more expensive than second-line 
ART and not as easily available in resource-limited settings. 
 
Third-line treatment currently consists of raltegravir (an integrase inhibitor), DRV/r (PI) and; etravirine 
(an NNRTI) (8, 54).  The WHO recommends that in countries where third-line ART is not readily 
available, patients who present with second-line treatment failure should continue on a tolerated 
regimen. This project focussed on LPV as the main component of second-line ART. 
 
1.4 A focus on Lopinavir-Ritonavir use: benefits and associated toxicities 
LPV/r is administered as a single drug (Kaletra) and is taken at a dose of 400mg/100mg twice daily (8). 
The use of LPV/r in ART may have other added benefits apart from the treatment of HIV. Ruel et al. 
(55) found that LPV/r used in ARV regimens in children also had anti-malarial effects. However, some 
adverse effects have been noted associated with LPV/r use and these include: hepatotoxicity, 
dyslipidaemia, diarrhoea and nausea [Table 1.3; (8, 56-60)]. Drug-induced hyperlipidaemia is of 
concern as it is associated with increased cardiovascular disease risk (58, 60, 61).  
The effects of LPV on cardiac function as well as on metabolism and vascular function have been 
investigated in rat models (58, 62). Yeung et al. (62) suggested that LPV (and other PIs) may affect 
responses of vascular smooth muscle to relaxing agents and hence pose a risk for cardiovascular 
diseases, while Reyskens et al. (58) reported changes in the contractile force of the heart and 





Table 1.3 Some toxic events that are associated with LPV/r use. 
Major Types of toxicity Risk factors References 
Attenuated cardiac function reported in a rat 
model 
 
PI-induced myocardial oxidative stress 
Decreased contractile force of the heart with PI 
treatment 
(58) 
Electrocardiographic abnormalities (PR and QT 
interval prolongation – indicate abnormal 
electrical activity of the heart) 
People with pre-existing conduction system disease 
Concomitant use of other drugs that may prolong 
the PR and/or QT interval (e.g. ATV) 
Congenital long QT syndrome  
Hypokalaemia 
(63, 64) 
Hepatotoxicity Underlying hepatic disease 
HBV and HCV co-infection  
Concomitant use of hepatotoxic drugs 
(56) 
Pancreatitis Advanced HIV disease  
Lipoatrophy or metabolic syndrome, 
dyslipidaemia 
Risk factors unknown (58, 60) 
Myocardial infarction  Partially explained by dyslipidaemia associated with 
PI use 
(59, 60) 
Hypertriglyceridaemia: increased non-HDL 
cholesterol levels 
Higher baseline triglyceride levels 
Total duration of ARV treatment 
 
(57) 
Gastroenteric symptoms: nausea or diarrhoea  (57) 
Adapted with modification from Table 7.15, WHO guidelines 2013(8). ATV: atazanavir; HDL: high-density lipoprotein; PI: 
protease inhibitor; PR and QT Interval indicate the rhythm of the heart. 
 
1.4.1. Structure and functional activity of Lopinavir 
LPV (also known as ABT-378) acts as a competitive inhibitor for HIV viral protease by forming a 
complex in the active site of the protease, thereby preventing the cleavage of the gag and gag-pol 
precursor proteins, by the affected protease, as illustrated in section 1.3.1 above (65, 66). LPV is the 
analogue of RTV (Fig. 1.4), and was developed to overcome the high resistance to treatment which 
was found to occur with RTV treatment. LPV shows greater efficacy against HIV than RTV and is 
associated with reduced risk of development of HIV resistance (67). Administered alone, LPV has a low 
bioavailability (68) due to high first-pass metabolism by cytochrome P450 (CYP) enzymes, CYP3A4 and 
CYP3A5 (69, 70) and efflux by MRP2 (multidrug resistance protein; (71). RTV is a potent inhibitor of 
CYP3A4 and, thus, the co-formulation of LPV with RTV (LPV/r, Kaletra) has allowed for improved 
bioavailability of LPV as RTV inhibits the metabolism of LPV by CYP3A4 (67) and has also been shown 
to inhibit the bio-activation of LPV by CYP3A4 (72). Figure 1.4 shows the comparative structures of 
RTV and LPV. The 2 molecules are similar in structure, except for an isopropyl group in RTV which is 
replaced by a cyclic urea moiety in LPV (Fig. 1.4). This cyclic group in LPV is shorter than the isopropyl 
group in RTV and, thus, interacts less with the valine at position 82 of HIV protease, a site prone to 
drug-resistant mutations. This contributes to the increased potency of LPV compared to RTV. Also, the 
cyclic urea in LPV allows for hydrogen bonding with aspartate 29 of HIV protease which results in 
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higher potency of LPV compared to RTV (66). Liu et al. (65) suggested that drug resistant mutations in 
HIV protease conferred less potency of LPV against the protease by weakening the interactions 
between LPV and the enzyme. 
 
 
Figure 1.4 The structure of Ritonavir and Lopinavir. The isopropyl group and cyclic urea moiety are 
circled in red. Figure adapted from Stoll et al. (66). 
 
1.5 Pharmacokinetics of Lopinavir 
Hurst and Faulds (73) reviewed the steady state pharmacokinetics of LPV, which is administered orally 
and taken twice daily with food. The bioavailability of the drug has been shown to be increased when 
taken with food containing a moderate-to-high fat content (74). At a dose of 400/100 mg, the acquired 
peak plasma concentration (Cmax) after administration of LPV is approximately 9.6 µg/mL and the 
Ctrough=5.5 µg/mL (75). For twice daily administration, the elimination half-life is about 4-6 hrs, whilst 
the oral clearance of LPV is 6-7 L/h (73, 74). In this section, proteins which play a role in the 
pharmacokinetics of LPV, including its distribution, disposition, metabolism and transport will be 







Table 1.4 Genes and proteins associated with pharmacokinetics and disposition of Lopinavir. 
Gene Protein Encoded by Gene Functional Significance Reference 
SLCO1B1 
 
OATP1B1 (organic anion 
transporting polypeptide) 
 
Solute carrier – localised to basolateral membrane of 
hepatocytes. Facilitates entry of substrate into cells. 
(76) 
CYP3A4 CYP3A4 Major phase I drug metabolising enzyme. Responsible 
for 30% drug metabolism in the body (along with 
CYP3A5). Found on the membranes of cells in the gut 







Phase I drug metabolising enzyme. Main CYP3A 
isoform in the kidney, but also expressed in the liver. 
CYP3A5 is approximately 80% homologous to 
CYP3A4. Large inter-individual variability exists in the 








Membrane transporter – drives efflux of non-
conjugated compounds across cell membranes using 
ATP-derived energy. 
(81) 
ABCB1 MDR1 (multidrug resistance 
protein; p-glycoprotein) 
Efflux transporter, uses ATP-derived energy to drive 
the transport of substrates. Expressed in the apical 
membrane of hepatocytes. 
(82, 83)  
NR1I2 PXR (pregnane X receptor) Ligand-activated nuclear receptor which induces the 
expression of certain drug metabolising enzymes, 
including CYP3A4, and transporters (e.g. MRP2 and 
MDR1). 
(78, 84) 





ORM (orosomucoid) – 






Plasma carrier protein for basic and lipophilic 
endogenous compounds or xenobiotics. 
Inflammatory marker – levels are increase in states of 
immune activation. Plasma levels vary according to 
different disease states including cancer, depression, 
genetic factors, HIV.  
(85-88)  
 Human Serum Albumin Binding of LPV (87) 
 
1.5.1. Lopinavir Distribution and Disposition 
As with other PIs, LPV binds to the α1-acid glycoprotein (AGP; also known as orosomucoid, ORM) 
within the plasma (89). ORM has a high affinity for lipophilic basic and neutral molecules, hence its 
binding of LPV which is a lipophilic, basic molecule (85, 90). Within the plasma, 99% of LPV is found 
bound to ORM; as reviewed by Ford et al. (89). However, the amount of drug bound to protein is 
influenced by protein concentrations (which may fluctuate), as well as on drug concentrations (85-
87). ORM expression is controlled by 2 genes on chromosome 9q31–34.1, AGP1 and AGP2, which 
encode ORM1 and ORM2, respectively. The binding of drugs to these 2 proteins is not well 
understood; some drugs bind preferentially to ORM1, whilst others to ORM2 (86). ORM1 is 
characterised by 3 codominant alleles: ORM1*F1; ORM1*F2; ORM1*S (91, 92) and ORM2 is 
monomorphic in most populations (92). The rs17650*S>*F polymorphism within AGP has been 
suggested to influence binding affinity of ORM to drug and was reported by Wang et al. (93) to 
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influence warfarin dosage requirements. The structure of the AGP gene has also been investigated 
African individuals (94-96). 
 
The disposition of LPV may be influenced by its binding to the ORM proteins. Circulating levels of ORM 
vary with the inflammatory status within an individual and, therefore, can vary between HIV-infected 
individuals (77, 88). As PIs are highly bound to ORM, the metabolism or clearance of these drugs may 
be influenced by varying concentrations or different phenotypes of the binding protein as the amount 
of free drug will be affected. This has been reported by Colombo et al. (86) who found that ORM1 
concentration had an influence on the disposition and clearance of LPV and IDV. However, the effect 
seen in the study was greater in IDV than in LPV. Contrary to the findings by Colombo et al. (86), it has 
later been reported that plasma drug binding protein concentration has little influence on antiviral 
activity of LPV/r (77). Although the total AUC12 (area under the concentration time curve) and LPV Cmax 
were influenced by ORM concentration, the amount of free LPV in the plasma and hence the antiviral 
activity of LPV were unchanged. The authors suggested that other factors, such as drug clearance, may 
account for this poor association. In the instance of levels of free LPV increasing due to a decrease in 
ORM levels, the clearance of LPV may also increase so that the amount free LPV in the plasma remains 
unchanged.  
 
In resource-limited settings, it has been proposed that ORM may be used as a marker for disease 
severity in HIV-1 infected mothers (88). It was reported that ORM concentration positively correlated 
with viral load and elevated ORM levels was associated with an increased risk in HIV-related deaths. 
However, it is not known whether the changing levels affect LPV levels or whether the allelic variation 
reported in Africans may influencing the binding of ORM substrates, including LPV.  
 
1.5.2. Hepatic Uptake Transporters: The Organic Anion Transporter Polypeptide 1B1 
Hepatic uptake transporters belong to the superfamily of solute carriers and are divided into the 
organic cation transporter and organic anion transporter families and the organic anion transporter 
polypeptide (OATP) family; reviewed by König et al. (97). Within the family, OATPs have ≥40% amino 
acid sequence similarity and in each subfamily, the proteins share more than 60% amino acid 
sequence identity (98). OATPs are a family of proteins which facilitate the uptake of drugs from portal 
blood into hepatocytes (99, 100). These proteins are involved in the active hepatic uptake of 
substrates through mechanisms independent of sodium, chloride and potassium gradients, 
membrane potential and ATP levels (82, 99, 101). These transporters are regarded as electroneutral 




OATP1B1 has been implicated in the pharmacokinetics of several drugs including PIs and statins, which 
are used in the management of cardiovascular disease (103, 104). It is also important to mention that 
PIs are also substrates of OATP1A2, OATP1B3 (105), but OATP1B1 is most important for the hepatic 
uptake of LPV. OATP1B1 consists of 691 amino acids and putatively contains 12 transmembrane 
domains (99, 106). Figure 1.5 shows the predicted structure of OATP1B1 which is expressed mainly in 
the liver and located at the basolateral (or sinusoidal) membrane of hepatocytes (76, 107, 108).  
 
Adequate functioning of the transporters and hence absorption of drugs is essential to ensure 
pharmacological action of orally administered drugs (82). The uptake of substrates into hepatocytes 
by OATP1B1 usually precedes the elimination of those substrates through metabolism or biliary 
excretion. Hence, impaired functioning of the transporter affects the pharmacokinetics of its drug 
substrates. The inhibition of OATP1B1 by certain drugs may play a role in drug-drug interactions which 
often lead to adverse drug reactions. For example, the anti-tuberculosis drug, rifampicin, has been 
shown to inhibit OATP1B1 and, hence, is not recommended for co-administration with PIs in patients 
with co-morbid TB and HIV infection (109). More specifically, LPV has been shown through in silico 
predictions and in vitro experiments, to be an inhibitor of OATP1B1 (110, 111).  
 
1.5.3. Phase 1 Drug Metabolism: Cytochrome P450 Enzymes (CYP3A4 and CYP3A5) 
Within the CYP3A subfamily of Cytochrome P450 (CYP) enzymes, CYP3A4 and CYP3A5 are the major 
isoforms expressed in the liver and small intestine, followed by CYP3A7 (expressed mainly in the foetal 
liver) and CYP3A43 (112). The genes encoding these enzymes are found on the same locus on 
chromosome 7 (80, 112). CYP3A4 is suggested to have arisen from duplication of exons in CYP3A5 
(113) and are very similar in sequence and share common substrates. These enzymes are responsible 
for Phase I metabolism of xenobiotics (involving oxidation and hydrolysis of substrates), and CYP3A4 
and CYP3A5 account for approximately 30% of the drug metabolism in the body and are thus the major 
drug metabolising enzymes in the body (114). Drug metabolising enzymes act by making xenobiotics 
more water-soluble. 
 
CYPs are haemoproteins, and are specifically oxidases found on the membrane of the endoplasmic 
reticulum in cells of the gut and liver (115, 116). Upon binding of the ligand to the enzyme, CYPs 
undergo conformational changes (114). As mentioned earlier, CYP3A4 and CYP3A5 are involved in the 
metabolism of LPV (70, 108, 117) into three major metabolites: M1, an oxidised derivative of LPV, M3 
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and M4, which are both epimers (compounds with the same chemical formula, but which differ in 




Figure 1.5 The major metabolites of Lopinavir metabolism (M1, M3 and M4). The cyclic urea unit 
around which M3 and M4 are epimers is circled in red. Figure adapted from Kumar et al. (118). 
 
1.5.4. Efflux Transporters: Multidrug resistance protein (MRP2) 
The multidrug resistance protein 2 (MRP2), encoded for by the ABCC2 gene, is a member of the ATP-
binding cassette superfamily (ABC) of transport proteins and is important in the biliary excretion of 
compounds from the liver; reviewed in Suzuki and Sugiyama (119). This 1541 amino acid protein is 
localised to the canalicular membrane of the liver (120, 121). It is also expressed on the apical 
membrane of enterocytes in the small intestine of rats (119, 122) and humans (123) and is also 
localised to the apical plasma membrane domain of the proximal tubule segments of the kidney in 
rats (124). MRP2 shows 49% sequence similarity to MRP1 (125) and as with other ABC transporter 
proteins, it contains the essential ATP-binding domain (121, 125). MRP2 has been shown to be 
involved in the ATP-dependent transport of glutathione, glucuronate and sulphate conjugates of 
lipophilic compounds (126). Products such as phase II metabolites of drugs are transported from 
within the liver across the hepatocyte canalicular membrane out of the liver (120). Loss of MRP2 
function has been linked to Dubin Johnson Syndrome which is a hereditary disorder, characterised by 




As with MDR1, MRP2 (but not MRP1 and other ATP-binding cassette transport proteins) has been 
demonstrated to be an efficient efflux transporter of PIs (71, 128). LPV has also been shown to be a 
substrate of P-glycoprotein (MDR1, coded for by the ABCB1 gene (71). When investigating transport 
of LPV by MRP2 in this study, Agarwal et al. (71) reported that in the presence of an inhibitor of MRP2, 
the efflux ratio of LPV was reduced from 2.9 to 1 in vitro, thus demonstrating that LPV is a substrate 
of MRP2. Van Waterschoot et al. (129) however found that P-glycoprotein, rather than MRP2 was an 
efficient efflux transporter of LPV when investigating transport in vitro and suggested that, overall, 
CYP3A activity was a better indicator of LPV oral pharmacokinetics than that of the transporter 
proteins. A further understanding into the importance of MDR1 and MRP2 in the transport of PIs, 
including LPV, is required overall, and also specifically in the sub-Saharan African context. For this 
study, MRP2, for which less is known, was selected for investigation. 
 
1.5.5. Pregnane X Receptor (PXR)  
The pregnane X receptor (PXR) is a nuclear receptor involved in inducing the promoter activity of drug 
metabolising enzymes (78) as well as efflux transporter proteins (130). In the case of drugs such as 
LPV/r, nuclear receptors act as sensors of the drug which lead to increased expression of CYP3A4/5 
and metabolism of the drug. After the drug binds to PXR, which is localised to the cytoplasm, PXR 
translocates to the nucleus where it forms a heterodimer with the Retinoid X Receptor (RXR). The 
heterodimer is then able to bind to nuclear response elements upstream of drug metabolising 
enzymes such as CYP3A4 and CYP3A5 (131). The efflux transporter proteins regulated by PXR include 
MRP2 and MDR1 (127, 130). The expression of SLCO1B1, which encodes the uptake transporter 
OATP1B1, is also regulated by PXR (106).  
 
Figure 1.6 below shows the proteins mentioned above in section 1.5, involved in the ADME 
(Absorption, Distribution, Metabolism and Excretion) process, specifically for LPV and the stages at 





Figure 1.6 Schematic representation of some proteins involved in uptake, distribution metabolism 
and efflux of Lopinavir in the liver. LPV: Lopinavir; LPV-OH: hydroxylated products of Lopinavir; 
MDR1: multidrug transporter, P-glycoprotein; MRP2: multidrug resistance-associated protein 2; 
OATP1B1: organic anion transporter 1B1; ORM: orosomucoid; PXR: pregnane X receptor. 
 
1.6 Lopinavir Pharmacogenetics 
Variation in genes that encode proteins involved in the metabolism and disposition of drugs is often 
associated with differences in plasma drug levels and patient drug responses. Single nucleotide 
polymorphisms (SNPs) within genes may play a role in the inter-individual variability in drug 
disposition either through changes in enzyme activity or expression levels (78). For instance, Svärd et 
al. (78) reported that Val140Met (valine to methionine substitution at amino acid 140) and Ala370Thr 




Genetic variation affecting the functioning of OATP1B1 may influence uptake of LPV into the liver, and 
hence its metabolism and clearance. The SLCO1B1 gene encoding OATP1B1 is located on the short 
arm of chromosome 12 as with other genes of the SLCO1 family (132). A highly reported SNP in 
literature is the rs4149056 (c.521T>C) SNP which leads to a Val to Ala change at amino acid 174 of 
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OATP1B1 (Fig 1.7). Although not much is known about OATP1B1 and the uptake of LPV, the 
rs4149056C allele has been associated with increased plasma concentrations of the drug in HIV-
positive patients (79, 105, 133). Therefore, it could be suggested that when the functional activity of 
OATP1B1 is decreased, less drug is taken up into the liver and more free drug is available in the blood 
stream which may lead to toxic effects. However, in the study by Schipani et al. (79) only 2% of the 
patients were homozygous for the minor allele and the c.521T>C SNP is known to have a low frequency 
in African populations (1-2%); therefore its significance in these populations may be low.  
 
Other SNPs in SLCO1B1, such as 388A>G (rs2306283), which results in an asparagine to aspartate 
substitution at amino acid 130 of OATP1B1 [Fig 1.7; (105)] may also be associated with the reduced 
activity of the protein contributing to joint effects. Four functionally distinct haplotypes are formed by 
combining the c.521T>C and c.388A>G SNP as these two SNPs are in linkage disequilibrium (LD), 
namely: c.521T/c.388A, *1A; c.521T; c.388G/c.521T, *1B; c.521C/c.388A, *5; c.521C/c.388G, *15. The 
SLCO1B1*5 and *15 haplotypes have been associated with decreased activity of OATP1B1 in vitro 
(134). However, little or no information is available on the distribution and therefore possible effects 
of these haplotypes in African populations. Moreover, African populations are the most affected with 
HIV/AIDS, and therefore more likely to use drugs that are substrates of OATP1B1, which means that 
possible deleterious effects of variation will be more prominent in these populations.  
 
Identifying the possible effect of SNPs in SLCO1B1 also aids in understanding drug-drug interactions. 
When drugs which are common substrates of OATP1B1 are used together, drug-drug interactions have 
been reported to occur such as for rifampicin (used in TB treatment) and atorvastatin when each are 
co-administered with LPV (110). In South Africa, especially in the Western Cape, many individuals are 






Figure 1.7 The predicted transmembrane structure of OATP1B1 encoded by SLCO1B1. The positions 
of non-synonymous SNPs of interest are circled in red. Figure adapted from Niemi et al. (106). 
 
1.6.2. CYP3A4 
The CYP3A4 gene is located on chromosome 7q21-22 (136) and is 27 kb in length, comprised of 13 
exons. Much inter-individual variability (up to 40 fold) has been characterised in the expression of 
CYP3A4 both in the intestine (137) and in the liver (138). Few functional genetic variants have been 
found within CYP3A4 (http://www.cypalleles.ki.se/cyp3a4.htm). It is also important to note that 
genetic variation is not homogenous across populations (139) and so a variant which may have a 
significant influence in protein function and hence drug disposition in one population, may have a 
weaker influence in another population.  
 
The CYP3A4*1B allele is encoded for by the -392A>G SNP in the promoter region of CYP3A4 (140, 141). 
As reviewed by Lamba et al. (138) and Werk et al. (112)(2014), there are conflicting reports on the 
functional significance of CYP3A4*1B allele. The SNP has been suggested to lie within a nifedipine 
(drug used to treat hypertension) specific binding element in CYP3A4 (141, 142) and was previously 
hypothesised to affect expression and, possibly, activity of CYP3A4 (140). This hypothesis was due to 
an association that was found between carriers of the CYP3A4*1B allele and prostate cancer in 
Caucasian men. However, Rebbeck et al. (140) do state that the association may have been due to an 
over-representation of the SNP in their 230 cases compared to the 94 healthy controls. This may be 
likely, as subsequent research has failed to prove an effect of this variant of expression or activity of 
the enzyme. The effect of the SNP on transcriptional activity of CYP3A4 was investigated through an 
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in vitro enzymatic activity assay where the hydroxylation of 6β-testosterone, a reaction catalysed by 
CYP3A4, was studied (141). Although much variability was shown in CYP3A4 activity, no differences 
were found between constructs harbouring the wild-type, CYP3A4*1 allele and constructs harbouring 
the CYP3A4*1B allele. Further studies have failed to prove an association of this allele with activity of 
the enzyme. The allele frequency varies among populations, ranging from 0.03 to 0.05 in Caucasians 
and 0.46 to 0.82 in Africans and African Americans (139, 143). 
 
A second SNP of possible functional significance is also found in a non-coding region of CYP3A4. After 
investigating various SNPs, Wang et al. (144) reported on an intron 6 SNP (CYP3A4*22, 
rs35599367C>T) to be functionally significant in a mixed population, representative of the population 
demographic in Columbia, Ohio. The study reported an association between CYP3A4*22 and statin 
dosage in patients being treated for hypercholesterolemia. In vitro expression analysis showed lower 
levels of CYP3A4*22 allele RNA compared to CYP3A4*1 allele RNA. Subsequent research has found 
the CYP3A4*22 allele to be associated with reduced protein levels and function in vitro (145). The 
intron 6 SNP is more prevalent in Caucasians (3 to 5%) than in Africans and African Americans (0 to 
2%). Hence, this SNP seems to be less significant in African populations, it has not yet been 
characterised in a sub-Saharan African cohort. Characterisation of these variants in a sub-Saharan 
population and investigating possible associations with LPV plasma levels may aid in explaining inter-
individual variability in treatment response.  
 
1.6.3. CYP3A5 
CYP3A5 is located on the same locus as CYP3A4 on chromosome 7q21-22 and, as with CYP3A4, CYP3A5 
is also comprised of 13 exons, but is 32 kb long. The expression of CYP3A5 is polymorphic as individuals 
with the wild-type CYP3A5*1 allele produces greater levels of full-length mRNA and express more 
CYP3A5 (146). The CYP3A5*1 allele has been reported to be in LD with the CYP3A4*1B allele in 
Caucasians and African Americans (147, 148). Two SNPs that have been shown to influence this 
polymorphic expression are an intron 3 SNP (6986A>G) and a SNP in exon 7 (14690C>T or G>A) of 
CYP3A5.  
  
The CYP3A5*3 (6986G) allele results in a truncated protein through alternative splicing mechanisms 
which result in a premature stop codon after amino acid 102 (146). This leads to degradation of the 
mRNA and hence low levels of CYP3A5 expressed from the CYP3A5*1 allele. The effect of this SNP on 
midazolam clearance and, hence, CYP3A5 activity has been investigated in a cohort of predominantly 
Caucasian cancer patients (149). The CYP3A5*3 was more prevalent than the CYP3A5*1 allele in the 
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study population. Although a significant association was found between carriers of the CYP3A5*3 
allele and reduced midazolam clearance, this result may be influenced by the low representation of 
CYP3A5*1 allele carriers. Subsequent studies have not found a role for CYP3A5*3 in midazolam 
clearance (148, 150, 151). The effect of the SNP has also been investigated on tacrolimus and 
cyclosporine clearance in Caucasian renal transplant patients (152) and on the metabolism of the PI, 
saquinavir, in HIV-seronegative black Tanzanian individuals (153). The CYP3A5*3/*3 genotype was 
reported to be associated with taclorimus dose-requirements and plasma trough levels but not on 
cyclosporine dose-requirements (152).  
 
Although LPV is also metabolised by CYP3A5, Rakhmanina et al. (108) found no association with the 
CYP3A5*3 allele (allele frequency G=0.417) and LPV concentrations in a cohort of HIV-infected 
children (a majority of African-American population). Estrela et al. (154) suggest that the inhibitory 
effects of RTV on CYP3A5-mediated LPV metabolism may eliminate the effect of polymorphisms within 
CYP3A5. It will be interesting to determine the relevance of this SNP for LPV pharmacokinetics in a 
sub-Saharan African population where the G allele has been found to be even less prevalent at a 
frequency of 0.09 (155). 
 
The CYP3A5 14690A allele (CYP3A5*6) results in the deletion of exon 7 from the protein (146). It is 
thought that the point mutation lies within an exon splicing enhancer region of exon 7, disrupting the 
splicing of the exon and leading to skipping of exon 7. The contribution of CYP3A5*6 to low expression 
of CYP3A5 in African populations is not well understood. 
 
The frequencies of CYP3A5*3 and *6 vary across populations. The CYP3A5*1 allele is more common 
in Africans than in Caucasians and Asians with the frequencies of CYP3A5*3 being on average 23%, 
85% and 29% respectively, and of CYP3A5*6 being 17%, 0% and 1% respectively (139). These 
frequencies may suggest that the role of CYP3A5*3 is more significant in Caucasians than in other 
populations.  
 
Daly (156) reviewed other missense mutations within CYP3A5 such as 27131-32insT (*7 allele); 
12952T>C at the intron 5 junction (*5 allele); 14665A>G (*4 allele) detected in a Chinese population; 
and a few other rare SNPs, 3699C>T (*8 allele) and 19386G>A (*9 allele). Rare variants have been 






The association of a few SNPs, including the ABCC2 rs717620 SNP (-24C>T) with LPV/r induced viral 
suppression was investigated in 69 Caucasian patients, 38 in whom the virus was suppressed (159). 
The SNP was determined not to be a determinant of reduced viral suppression in these patients. A 
trend towards association was only present when the joint effects of the rs4149056 (in SLCO1B1), 
rs6945984 (in CYP3A) and rs717620 were determined in a univariate analysis, however the effect did 
not remain when a multivariate analysis was conducted. The SNP has been reported to result in 
decreased expression and activity of the protein (160). According to data from 1000 Genomes 
(http://spsmart.cesga.es/search.php?dataSet=engines), rs717620 SNP has been reported to have a 
low frequency in African populations (Yoruba population, Nigeria; and Luhya population, Kenya) of 
0.033 compared to 0.211 in Caucasians. The study by Glass et al. (159), in which an association with 
rs717620C>T and LPV/r induced viral suppression was observed, was conducted in a Caucasian 
population and thus the effect reported may be more relevant in this population which has a higher 
frequency of the variant. 
 
In a study on Chinese individuals with epilepsy investigating the effect of SNPs in ABCC2 on epileptic 
drug resistance (161), it was reported that rs717620C>T was in LD with a SNP in exon 10 of the gene 
(c.1249G>A, rs2273697; D’=0.694). Although an association was identified with the -24T allele and 
drug resistance, no association was identified with the c.1249G>A SNP and drug resistance. The 
frequency of this variant is reported at 0.199 in African populations, and slightly lower at 0.134 in 
Chinese according to 1000 Genomes data (http://spsmart.cesga.es/search.php?dataSet=engines).  
 
In an in vitro study investigating the effects of another SNP, rs8187710 (c.4544G>A), on MRP2 activity, 
this variant was suggested to decrease the efflux activity of the transporter (81). Polymorphisms that 
decrease the activity of this efflux transporter may result in drug failure associated with reduced 
excretion of the metabolised drug from the liver. The c.4544G>A SNP (which results in a cysteine to 
tyrosine transition at position 1515 of the protein) in ABCC2 has been suggested to result in toxicity 
of certain drugs due to decreased cellular efflux, for example, of doxorubicin and flavopiridol (both 
used in cancer treatment) (162, 163). Interestingly, both these drugs are also substrates for the uptake 
transporter OATP1B1. Elens et al. (81) reported that this 4544G>A SNP resulted in increased cellular 
accumulation of LPV in transfected cells. In cells with the G variant, the intracellular accumulation of 
LPV was almost 3 times lower than in cells with the variant allele, suggesting that the SNP reduces the 
functional activity of the protein (81). It has been reported to be in a haplotype with rs17222723 
(c.3563T>A) (164) and both are suggested to be associated with non-alcoholic fatty liver disease (165). 
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These are just a few of the SNPs which may possibly have an effect of the activity of ABCC2 and hence 
on its transport of LPV/r. It would be important to study the importance of this gene in LPV/r 
pharmacogenetics, identifying any important SNPs from the above mentioned or even SNPs not 
previously investigated. This would be of particular interest to us in a sub-Saharan African context. 
 
1.7 Aims and Objectives 
The aims of this study were, then, firstly, to identify variation in genes that may affect LPV disposition 
and compare the frequencies of the identified variants with those of other populations. The second 
aim was to identify the role of these variants with respect to plasma LPV levels to possibly be used as 
markers for LPV response within the specified populations. 
 
In order to achieve these aims, the objectives were to: 
 Recruit patients on LPV/r regimen 
 Identify genes commonly implicated in LPV disposition from the literature 
 Identify variation in the selected genes associated with variable LPV response 
 Determine the genotypes of patients at loci of interest 
 Determine the allele frequencies for the selected variants 






2. Materials and methods 
This was a cross-sectional study involving Bantu Africans recruited from South African and Malawian 




Recruited participants were 86 unrelated, adult individuals with HIV/AIDS on ART regimen with LPV/r. 
The inclusion criteria included participants who identified themselves as Bantu African for at least 
three generations, were at least 18 years of age and had been on ARV treatment for at least six 
months. In addition, participants had to give informed written consent for participation and agree to 
the accessing of their medical records. The patients were placed on second-line ART after failing first-
line ARV therapy, either due to adverse reactions experienced while on first-line treatment or failure 
of the treatment to suppress the virus (<20 to 75 copies/mL). First-line therapy was 3TC+AZT or 
3TC+NVP+d4T or TDF. Fifty-two individuals from Malawi (Queen Elizabeth ART Clinic, Blantyre); and 
thirty-four individuals from South Africa (Helen Joseph Hospital, Thembalethu, Johannesburg) were 
recruited after giving written and verbal informed consent. Participants were on treatment for at least 
6 months up to 9 years at the time of recruitment. The sample size was small due to there being few 
participants on second-line treatment. Blood samples were collected from these patients, in EDTA 
(ethylenediaminetetraacetic acid)-coated tubes and kept at -20°C until subsequent DNA extraction 
and genetic analysis, and for LPV plasma level detection. Patients’ demographic information was 
obtained from their medical records and the CD4 count, viral load and liver enzyme levels were also 
available from clinical patient records. Ethical approval for the study was obtained both from the 
Malawi University College of Health Sciences and the University of Cape Town, Faculty of Health 
Sciences Human Research Ethics Committee (HREC REF: 439/2013). 
 
2.2 DNA Isolation 
2.2.1 DNA Isolation using GenElute™ Blood Genomic DNA Kit 
For the blood samples collected from Malawi, the GenElute™ Blood Genomic DNA Kit (Sigma-Aldrich, 
St Louis, USA) was used for the extraction of DNA from the blood samples according to the 
manufacturer’s instructions. For each sample, whole blood that had been collected in a tube coated 
with an anti-coagulant. 10 µL of proteinase K (20 mg/mL) was added to 250 µL of whole blood in a 1.5 
mL eppendorf tube. 20 µL of RNase A solution was added to the mix (in order to obtain RNA-free 
genomic DNA); the contents were mixed by gently inverting the tube 6 to 8 times and the tubes were 
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then incubated for 2 min at room temperature. The cells were lysed by adding 1 volume (275 µL) of 
lysis solution C to the samples, followed by vortexing the tube for 15 s. The samples were then 
incubated at 55°C for 1 hour. 250 µL of the column preparation solution was added to the GenElute 
miniprep binding column and centrifuged at 12 000 x g (rcf) for 1 min; this solution allows DNA to bind 
efficiently to the column to obtain good yields after isolation. The eluted liquid was discarded and the 
column left to stand for approximately 10 min. In preparation for binding of the DNA, 275 µL of 
absolute ethanol (95% - 100%) was added to the lysate from the cell lysis step and mixed thoroughly 
by mixing for 5 to 10 s. 650 µL of the contents of the tube were transferred to the treated column; the 
column was centrifuged at ≥6500 x g for 1 min. The process was repeated twice, with the collection 
tube being discarded each time and replaced with a new one. 250 µL of prewash solution (diluted with 
110 µL absolute ethanol prior to use; the solution helps to remove contaminants in blood samples 
that aren’t fresh) was added to the column and centrifuged at ≥6500 g for 1 min. The collection tube 
containing the eluted liquid was discarded and replaced with a new 2 mL collection tube. 250 µL of 
wash solution (diluted with absolute ethanol prior to use) was added to the column and centrifuged 
for 4 min at maximum speed (12 000 g). It is important to ensure that there is no residual ethanol 
remaining in the column after this step which is just before the DNA elution step. Ethanol is thought 
to interfere with downstream processes such as polymerase chain reaction (PCR) and sequencing 
through inhibition of used enzymes. The collection tube containing the eluted liquid was discarded 
and replaced with a new 2 mL collection tube. After the ethanol wash of the column, the DNA is 
assumed to have bound to the column, thus, 200 µL of elution solution (10 mM Tris-HCl, 0.5 mM EDTA, 
pH 9.0; Tris-EDTA buffer prevents the degradation of the DNA) is added directly into the centre of the 
column. The solution was incubated overnight at room temperature to increase the efficiency; and 
the following day the column was centrifuged at ≥6500 g to elute the DNA. The collection tubes 
containing the eluted pure genomic DNA were stored at -20°C for long-term use. 50 µL aliquots of 
DNA were stored at -4°C as working solutions for downstream analyses.  
 
2.2.2 DNA Isolation using a Salting out Extraction Method 
For the blood samples collected from the South African participants, DNA was extracted using a salting 
out extraction method adapted from Gustafson et al.’s (166) protocol. According to this method, 4 mL 
of blood thawed at room temperature was diluted with phosphate buffered saline (PBS) after which 
samples were centrifuged at 2200 x g for 10 min. The supernatant was then poured off and the pellet 
re-suspended in 10 mL Sucrose Triton X-100 lysis buffer (see recipe in appendix). This buffer is made 
up 1 M Tris-HcL (pH 8; provides the necessary pH for the buffer), 1 M MgCl₂ (provides Mg²⁺ ions which 
act as co-factors for the enzymes in the solution), Triton X-100 (a detergent which solubilises proteins 
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by manipulating hydrophobic-hydrophilic interactions of membranes) and sucrose (increases the 
osmolarity of cells allowing water to flow in so that the cells burst). The tubes were placed on ice for 
5 min and then centrifuged at 2200 g for 10 min. The supernatant was carefully poured off and the 
pellet resuspended in 3 mL of T20E5 (pH 8.0; see protocol for making the solution in appendix A) and 
the tubes inverted repeatedly to mix. 200 µl of 10% SDS (sodium dodecyl sulphate) was added and 
again the tubes were inverted, followed by the addition of 100 µL of proteinase K (final concentration 
of 250 µg/mL) and mixing of the solution. SDS breaks down cell membranes to release lipids and 
proteins, and proteinase K digests proteins, particularly DNase and RNase enzymes. The samples were 
incubated overnight in a water bath at 45°C. The following day, 1 mL of saturated NaCl was added to 
the samples to precipitate the proteins and each sample was mixed by vortexing for 15 s, and then 
centrifuged at 2400 g for 30 min. The DNA-containing supernatant was transferred to a new sterile 
polypropylene tube and 8 mL of 100% ethanol (kept at room temperature) was added and the tubes 
were gently agitated and the DNA was spooled using a glass Pasteur pipette. The DNA was transferred 
to an eppendorf tube and washed by the addition of 1 mL 70% ice-cold ethanol. The samples were left 
to air dry after which the DNA was dissolved in 150 µL of 1X TE buffer (pH 8.0). 
 
2.2.3 DNA Integrity – NanoDrop™ Spectrophotometry 
After DNA extraction, it is good laboratory practice to determine the quality of the isolated DNA by 
checking its integrity and purity. The integrity of extracted DNA was determined by analysis of 100-
500 ng on a 1.5% agarose gel using electrophoresis, whilst the purity of the DNA was measured using 
a NanoDrop™ 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, USA). Through 
spectrophotometry using the NanoDrop, we were able to measure the absorbance of DNA at 260 nm 
in order to determine its concentration. The NanoDrop™ Spectrophotometer makes use of fibre optic 
technology and surface tension to measure the absorbance of nucleic acids, in this case DNA. 1uL of 
sample is loaded onto an optical surface and held in place between two optical surfaces that define 
path length in a vertical direction (167).  The concentration of DNA isolated using the GenEulute Blood 
Genomic DNA kit ranged from 6.19 to 91.19 ng/µL, while that of the DNA isolated using the salting out 
extraction method ranged from 3.48 to 624.53 ng/µL. The A₂₆₀/A₂₈₀ ratio indicates the purity of the 
DNA. For DNA that is pure from contaminants such as alcohol, protein and RNA, a ratio of 1.7-1.9 is 
expected. The 260/280 ratios obtained with spectrophotometry ranged from 1.5 to 2.1. The A₂₆₀/A23₀ 
ratio is a secondary measurement of DNA purity, a value below the expected 2.0-2.2 may indicate the 
presence of contaminants such as phenol, carbohydrates and EDTA which absorb light at a wavelength 
of 230 nm. The values obtained for the A260/A280 ranged from 0.4 to 4. The values outside the 
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appropriate range may have been indication of alcohol, or protein impurity. However, this did not 
impact on downstream investigations. 
 
2.2.4 DNA Integrity – Agarose Gel Electrophoresis 
Agarose gel electrophoresis is a method used to analyse DNA by separating DNA molecules based on 
size through the pores in a gel. The percentage of the gel determines the size of the pores in the gel, 
and hence the size of DNA fragments that can be separated on the gel. Small fragments (50 to 300 bp) 
will require a high percentage gel (2 to 5%), whilst larger fragments (e.g. 500 to 1500 bp) require a 
lower percentage gel (0.8 to 1.5%). To make the gel, agarose powder was dissolved in 1X Tris-Borate 
EDTA (TBE) buffer and melted for 3 to 5 min depending on the concentration of the gel (high 
percentage gels required a longer heating time to dissolve the agarose). Once melted, the solution 
was allowed to cool to a temperature around 55°C after which the nucleic acid stain GR Green (5 
µL/100 mL of solution) was added. Nucleic acid stain, GR Green, facilitates the visualisation of DNA 
under UV light. Once the GR Green had been homogenously mixed, the gel solution was poured into 
casting trays with combs inserted (to create wells in the gel), and the gel was left to set for 
approximately 30 min.  
 
After the gel had set, the combs were removed creating wells where samples were loaded into the 
wells, for integrity evaluation. The gel was placed in a tank containing 1X TBE buffer, in which a current 
was run. We used the Enduro™ power pac (Labnet, Woodbridge, USA) with a maximum output of 300 
V or 500 mA. The current allows the DNA to migrate from the cathode (negative end) of the tank 
towards the anode (positive end) of the tank, as DNA is negatively charged, thus the wells should be 
placed closest to the cathode. The voltage that is set determines the speed at which the DNA migrates; 
typically the standard is 5 V/cm (168). Small fragments migrate faster and further than large fragments 
through the gel. Before loading the samples into the wells, 3 µL of a 1X loading dye containing two 
dyes (Bromophenol Blue and xylene cyanol FF) and Glycerol (Thermo Scientific, Wilmington, USA) was 
mixed with 5 µL of the sample. The dyes allow the tracking of the DNA as it migrates on the gel; 
whereas, glycerol facilitates the sample to sink to the bottom of the wells. A molecular weight marker 
is often used in agarose gel electrophoresis to guide us on the size of the DNA molecules being 
separated. In this, case, the GeneRuler™ 100 bp plus ladder (Thermo Fisher Scientific, Wilmington, 
USA) was used as the molecular weight marker was loaded into one of the wells. After electrophoresis, 
agarose gels were placed in the FireReader V4 UV gel documentation machine (UVitec Limited, 
Cambridge, UK) so that the DNA fragments could be visualised under UV light, and an image was 




2.3 Genetic Characterisation of Samples 
The extracted DNA was used for genetic characterisation of genes that are known to play a role in the 
disposition of LPV and these include CYP3A4, CYP3A5, SLCO1B1, and ABCC2 (Table 2.1). Each of these 
genes was annotated using the PerlV5 program and the SNPs to be genotyped were selected based 
on literature and with respect to their frequency in populations, as well as on their possible functional 
effects. The targeted SNPs include c.-392A>G (rs2740574) and a SNP in intron 6 (rs35599367C>T) in 
CYP3A4; c.6986A>G (rs776746) and 14690C>T (rs10264272) SNPs in CYP3A5; c.388A>G (rs2306283) 
and c.521T>C (rs4149056) in SLCO1B1; c.1249G>A (rs2273697), c.-1019A>G (rs2804402), and c.-





Table 2.1 Variation in genes associated with Lopinavir disposition. 
Gene SNP Allele Possible Functional Effect of SNP 








CYP3A4 rs2740574A>G  *1B May influence drug plasma levels 
↓ CYP3A4 protein levels  
0.7-0.8 0.68 0.023 0.00 
rs35599367C>T *22 May influence CYP3A4 expression 
and activity 
0.00 N/D 0.025 0.00 
CYP3A5 rs776746G>A *3 Loss of CYP3A5 function 0.83-0.87 0.63-0.74 0.04-0.06 0.26-0.34 
rs10264272C>T *6 Deletion of exon 7 of gene 0.14-0.25 0.115 0.00 0-0.01 
SLCO1B1 rs4149056T>C 
 
*5 Amino acid change in substrate 




rs2306283A>G *1B Possibly associated with reduced 
function of SLCO1B1 
0.81 0.73-0.81 0.30-0.44 0.65-0.8 
ABCC2 rs717620C>T  Decreased promoter activity, 
mRNA expression and duodenal 
protein content 
0.03-0.06 N/D 0.15-0.2 0.15-0.22 
rs2273697G>A  In LD with rs717620C>T 0.21-0.25 0.1-0.24 0.146-0.26 0.078-0.12 





rs17222723T>A  Haplotype formed with 
rs8187710G>A 
May be associated with non-





The online tools, Primer Blast (www.ncbi.nlm.nih.gov/tools/primer-blast/) and Oligo Analyzer® 3.1 
(Integrated DNA Technologies Inc., USA; eu.idtdna.com/analyzer/Applications/OligoAnalyzer/) were 
used in the design and analysis of primers. Table 2.2 presents a summary of the methods and 





Table 2.2 Primers and genotyping conditions for the targeted SNPs. 
Gene SNP/Region Method Primers Size (bp) Ta° 
















g.14690G>A PCR-RFLP F: 5ʹ-TGGAAGATGATTCAGCAGATA-3ʹ 
R: 5ʹ-GTGGGGTGTTGACAGCTAAAG-3ʹ 
495 58°C 




Exon 6 Sequencing F: 5ʹ-ACAAGGAAACTGCAAAAGGA-3ʹ 
R: 5ʹ-ATTATATTAAGCAAAGGACTATTGAAAGAG-3ʹ 
Internal R: 5ʹ-AATCATCAATGTAAGAAAGCC-3ʹ‡ 
1436 64°C 
ABCC2 c.1249G>A PCR-RFLP F: 5ʹ-GGGCAAAGAAGTGTGTGGAT-3ʹ 
R: 5ʹ-ACATCAGGTTCACTGTTTCTCCCA-3ʹ 
303 61° 
-1632 to -1419 Sequencing F: 5ʹ-AAAAGTGTCTGTTCAAGTCC-3ʹ 
R: 5ʹ-GTGAATTGTATGGACCTTGT-3ʹ 
214 51°C 
-1157 to -908 Sequencing F: 5ʹ-GGATACCGCATGGGTGGTTC-3ʹ 
R: 5ʹ-ACTACAGGCACATGCCCACA-3ʹ 
249 60°C 
N/A: Not applicable 
†A second reverse primer was designed for sequencing of the SLCO1B1 exon 5 region (NCBI reference sequence: 
NC_000012.12), replacing the reverse primer used in the PCR amplification of that region. 
‡ An internal reverse primer was designed for sequencing of the SLCO1B1 exon 6 and 7 region (NCBI reference sequence: 
NC_000012.12) to cover the gap not covered by sequencing with the forward and reverse primers.  
 
2.3.1 Description of Genotyping Techniques Used in this project 
2.3.1.1 Principle of PCR Restriction Fragment Length Polymorphism 
PCR restriction fragment length polymorphism (PCR-RFLP) allows for the identification of specific 
variants through cleavage by DNA restriction enzymes which each recognise a specific restriction site 
(a sequence of nucleotides). RFLP is only used where the variant of interest creates or abolishes a 
restriction site making it possible to use patterns of restriction/digestion as markers for presence or 
absence of mutations. Fragments are separated by agarose electrophoresis to identify the fragment 
sizes achieved after enzymatic digestion, and the genotypes are thus determined.   
 
NEBcutter (New England Biolabs® Inc., Beverly, USA) and RestrictionMapper 
(http://www.restrictionmapper.org/) were used to select suitable restriction enzymes for the 
characterisation of each of the SNPs. Briefly, an input sequence flanking the SNP of interest was pasted 
into the search box (typically the sequence of the amplified PCR fragment) and the program then 
generated an output of the possible restriction enzymes that would cleave that fragment, their 
restriction sites and the positions at which they would cleave (169). Each restriction enzyme used was 
selected based on the presence of the SNP of interest within the restriction site i.e. a restriction site 
was created or abolished in the presence of the SNP. 
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2.3.1.2 TaqMan® SNP Genotyping Assay  
The TaqMan assay is a real-time PCR method that makes use of fluorescent probes to identify specific 
variants within genes (170). As with conventional PCR, primers are used to amplify the region of DNA 
containing the SNP of interest. The assay also contains 2 additional labelled minor groove binder 
probes which are short (20 nucleotides) sequence of oligonucleotides that are complementary to 
either the wild-type allele, or the variant allele. Each probe has a quencher dye at one end, and a 
reporter dye at the other end. The quencher dye absorbs baseline fluorescence emitted by the 
reporter dye when the two are in close proximity. When the probe binds to its complementary 
sequence, the probe is cleaved through the 5ʹ nuclease activity of the Taq DNA polymerase as it 
extends the newly made strand. The reporter dye is able to release fluorescence. If the probe does 
not bind, it is not cleaved and the reporter and quencher dyes remain in close proximity and only low 
levels of fluorescence are emitted.  
 
2.3.1.3 Sequencing to confirm genotypes or to identify novel variants 
The Principle behind Cycle Sequencing 
Cycle sequencing was performed to confirm the genotypes determined for CYP3A4 and CYP3A5 
variants, and to identify novel variants in SLCO1B1 exon 5, 6 and 7 and their exon-intron junctions. 
Cycle sequencing is based on the method published by Sanger et al. (171) involving dideoxy-
nucleotides (ddNTPs) that terminate synthesis of newly formed chains at specific nucleotide residues. 
Unlike deoxynucleotides (dNTPs) used in the synthesis of DNA strands, ddNTPs lack a 3ʹ-hydroxyl 
group essential in the formation of phosphodiester bonds during synthesis of the DNA strand. This 
prevents the chain from being further extended and results in the termination of synthesis of that 
strand. Cycle sequencing is a fluorescence-based method which uses fluorescent dyes to label the 
extension products (172, 173) and the products are analysed by capillary electrophoresis.  
 
Sequencing Method 
Following PCR amplification, products were purified using FastAp™ Thermosensitive alkaline 
phosphatase (Thermo Scientific, Wilmington, USA) and Exonuclease 1 (Exo 1; Thermo Scientific, 
Wilmington, USA) to remove unincorporated dNTPs and excess primers. FastAp™ is involved in the 
degradation of nucleotides through dephosphorylation, while Exo 1 is a hydrolytic enzyme which 
degrades single-stranded molecules in the reaction. 5 µL of PCR product was added to a mixture 
containing 1 µL (1 U) of FastAp™, 2 U of Exo 1 and 13.9 µL of distilled water (dH2O; obtained from 
Sabax) to a total volume of 20 µL. The mixture was incubated at 37°C for an hour followed by 15 min 
at 75°C to inactivate the enzymes. 
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To sequence amplified fragments either to confirm the genotypes determined through RFLP and 
TaqMan or to identify novel variants, 4 µL of dH2O, 2 µL of 5X Sequencing Buffer (Life Technologies, 
California, USA), 1 µL of BigDye® Terminator v3.1 Ready Reaction Mix (Life Technologies, California, 
USA), 1 µM primer (reverse or forward depending on the position of the SNP) and 2 µL of purified PCR 
product were added to each tube or well and mixed well by vortex pulsing. The Applied 
Biosystems®2720 Thermal Cycler (Life Technologies, California, USA) was used for sequencing with 
cycling conditions set at 98°C for 5 min followed by 35 cycles of 96°C for 30 s, 55°C for 15 s and 60°C 
for 4 min. Following the sequencing reaction, sequenced products were placed at 4°C or -20°C until 
purification of the products. 
 
Ethanol Precipitation of Sequenced Products 
Purification of the sequenced products is necessary to remove unincorporated dNTPs and labelled 
ddNTPs which may interfere with analysis of fluorescent signals during capillary electrophoresis. 
Sequenced products were purified by ethanol precipitation. For each 10 µL sequenced product, 22 µL 
cold absolute ethanol, and 1 µL of 3 M NaOAc (pH 5.21) was added to a 1.5 mL eppendorf tube. The 
sequenced product was then added to the tube, the tubes were vortexed and placed at -20°C 
overnight. The following day, the samples were centrifuged at 10 RPM for 10 min and the supernatant 
was then carefully removed by pipette. To each tube, 35 µL of 70% ethanol was added and again the 
tubes were vortexed and centrifuged at 10 RPM for 10 min. The supernatant was removed and the 
tubes were left open for at least 2 hrs (covered with paper towel) to allow the remaining ethanol to 
evaporate. Once dry, samples were resuspended in 10 µL dH2O and placed in the fridge at 4°C until 
analysis by capillary electrophoresis. 
 
Capillary Electrophoresis 
The ABI Prism 3130xl Genetic Analyzer (Applied Biosystems®, Life Technologies, California, USA) was 
used for capillary electrophoresis. This is a 16-capillary electrophoresis instrument which allows for 
the sequencing of read lengths of more than 500 bases. A 36 cm capillary array was used to achieve 
up to 600 base length reads, with POP-7™ polymer. To prepare the plate for electrophoresis, 5 µL of 
sample was added to each well on a MicroAmp® Optical 96-well reaction plate (Applied Biosystems®, 
Life Technologies, California, USA) and 5 µL Hi-DI (highly deionised) Formamide (used as an injection 
solvent for capillary electrophoresis) was added to each sample. Samples are analysed in groups of 2 
columns (16 wells) at a time, thus when analysis fewer than 16 samples, 10 µL of Hi-Di was added to 
the empty wells. The reaction plate was sealed with a septa mat to prevent evaporation of samples 
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while still allowing the capillaries access through the pierce-able septa. The sequenced products were 
denatured by placing the reaction plate in a thermal cycler at 94°C for 5 min.  
 
2.3.2 Characterisation of variation in SLCO1B1 
To identify novel SNPs within the region from exon 5 to 7 of SLCO1B1 (see Fig. 2.1), the ABI Big Dye® 
Terminator v3.1 Cycle Sequencing Kit (Life Technologies, California, USA) was used for sequencing and 
products were analysed on the ABI Prism 3130 Genetic Analyzer. For sequencing of the region 
containing exon 5, a 1448 bp fragment was amplified by PCR using the following primers, forward: 5ʹ-
TAT CTT TCT TGC TGG ACA CTT C-3ʹ; reverse: 5ʹ-CAC ACA GAA GAT CAC CTC AA- 3ʹ. The PCR conditions 
used for amplification on the T100™ Thermal Cycler (Bio-Rad, Hercules, USA) were: 94°C for 3 min, 
94°C for 30 s, followed by 35 cycles of 65°C for 30 s, 72°C for 1 min 30 s, and 72°C for 7 min.  
 
For sequencing of the region containing exon 6 and exon 7, a 1436 bp fragment was amplified by PCR 
using the following primers, forward: 5ʹ-ACA AGG AAA CTG CAA AAG GA-3ʹ; reverse: 5ʹ-ATT ATA TTA 
AGC AAA GGA CTA TTG AAA GAG-3ʹ.The PCR conditions used for amplification were: 94°C for 3 min, 
94°C for 30 s, followed by 35 cycles of 64°C for 30 s, 72°C for 1 min 30 s, and 72°C for 7 min.  
Amplified fragments were purified for downstream sequencing, as described in section 2.3.1.3 above. 
To sequence the amplified fragments, 3.5 µL of dH2O, 2 µL of 5X sequencing buffer (Life Technologies, 
California, USA), 2 µL of BigDye® Terminator v3.1 Ready Reaction Mix (Life Technologies, California, 
USA), 1 µM primer (refer to Table 2.2 for primers used for sequencing) and 1.5 µL of purified PCR 
product were added to each tube or well and mixed well by vortex pulsing. The Applied 
Biosystems®2720 Thermal Cycler (Life Technologies, California, USA) was used for sequencing with 
cycling conditions set at 98°C for 5 min followed by 35 cycles of 96°C for 30 s, and 60°C for 4 min and 
15 s. Following the sequencing reaction, sequenced products were placed at 4°C or -20°C until 
purification of the products. The sequences were assembled and aligned using DNAstar Lasergene® 





Figure 2.1 Schematic diagram of SLCO1B1 gene showing the regions that were genotyped. The gene 
is 108.6 kb long ad has 14 coding exons (blue boxes). Brackets indicate the regions which were 
sequenced, with two known SNPs of interest in exon 5 and exon 6 shown with arrows.  
 
2.3.3 Characterisation of variation in CYP3A4 and CYP3A5 
The CYP3A family genes (CYP3A4, 3A7 and 3A5) are located in a cluster on the same locus on 
chromosome 7 and a total of 4 SNPs (2 in 3A4 and 2 in 3A5) were genotyped for in this project. CYP3A4 
is 27 kb in length, whilst CYP3A5 is 32 kb in length (Figure 2.1).  
 
 
Figure 2.2 Schematic diagram of position and orientation of CYP3A family genes as on the NCBI gene 
database. Diagram not drawn to scale. Numbers above the black line indicate the position of the 
genes in the genome (Reference sequence: NC_000007.14).  
 
PCR-RFLP was used to genotype the rs2740574A>G SNP in CYP3A4, and the rs10264272C>T and 
rs776746A>G SNPs in CYP3A5.  
 
2.3.3.1. CYP3A4 rs2740574A>G SNP characterisation 
The position of the genotyped SNPs within CYP3A4 is indicated in Fig. 2.3. PCR-RFLP of a 448 bp 
fragment within the CYP3A4 promoter containing the rs2740574A>G SNP was performed using 
primers and a restriction enzyme as reported by Tavira et al. (174) (Table 2.2). The Bio-rad T100™ 
Thermal Cycler (Bio-rad Laboratories Inc, Hercules, CA) was used for PCR amplification, set at the 
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following conditions: 94°C for 3 min, 35 cycles of 94°C for 30 s, 64°C for 60 s, 72°C for 1 min, 72°C for 
10 min. The following primers were used for PCR, forward: 5ʹ-GGA CAG CCA TAG ARA CAA GGG CT-3ʹ; 
reverse: 5ʹ-AGG TTT CCA TGG CCA AGT CT-3ʹ. PCR conditions were carried out as follows: initial 
denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, annealing at 64°C for 60 s, and 
72°C for 60 s; final extension at 72°C for 10 min. The T100™ Thermal Cycler (Bio-Rad, Hercules, USA) 
was used for the PCR reaction. The presence of the correct fragment was confirmed by agarose gel 
electrophoresis, on a 1.5% Agarose™ Gel using SeaKem® LE Agarose (Lonza, Rockland, USA). 3 µL of 
1X loading dye was added to 5 µL of product and loaded into the well. Gels were run for 45 to 60 min 
at 100 V.  
 
The PCR product was digested with FspBI (BfaI) enzyme (Thermo Fisher Scientific, Wilmington, USA) 
by incubating overnight at 37°C. Digested products were then analysed on a 5% nusieve gel made up 
using Nusieve™ 3:1 agarose (Lonza, Rockland, USA) according to the suppliers instructions and 
electrophoresed for 120 min at 80 V, followed by 60 min at 120 V. In the presence of the A allele, the 
448 bp fragment was cleaved twice to yield three fragments, 256, 170 and 22 bp. In the presence of 
the variant G allele, the 448 bp fragment was cleaved once to yield two fragments of 278 and 170 bp. 
 
2.3.3.2. CYP3A4 Intron 6 rs35599367C>T SNP Characterisation 
To genotype the intronic (rs35599367C>T; CYP3A4*22) SNP in CYP3A4, a TaqMan assay was 
performed using TaqMan® SNP Genotyping Assay (Assay ID: C__59013445_10) and TaqMan Universal 
Master Mix (Life Technologies, California, USA). See section 2.3.1.2 for a brief description of the 
technique. 
 
To confirm the genotypes, sequencing was performed using the following primers, forward: 5ʹ-GCT 
CTG GGC ATA GAG TCT GC- 3ʹ; reverse: 5ʹ-ATG CAT GCA ACA GGA AAC CC- 3ʹ. PCR, to amplify a 364 bp 
fragment, was performed on the T100™ Thermal Cycler (Bio-Rad, Hercules, USA): initial denaturation 
at 94°C for 3 min, followed by 30 cycles of 94°C for 30 s, 59°C for 30 s, and 72°C for 40 s; and final 
extension cycle of 72°C for 10 min. The amplified fragments were then separated on a 1.5% agarose 
gel to confirm amplification of the correct fragment. The post-PCR clean-up of the amplified fragments 
was performed using FastAp™ thermosensitive alkaline phosphatase and Exo 1 enzymes for the 
removal of unincorporated dNTPs and primers. Cycle sequencing was performed on the purified PCR 
product under these conditions: 98°C for 5 min, 96°C for 30 s, 58°C for 15 s and 60°C for 4 min. The 
sequenced products were purified by ethanol precipitation. For the sequencing analysis, 5 µL of each 
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product was added onto 96 well ABI plates, to which 5 µL Hi-Di formamide (Life Technologies, 
California, USA) was added to resuspend the DNA sample.  
 
 
Figure 2.3 Schematic diagram of CYP3A4 gene. The position of SNPs that were genotyped are 
indicated with arrows. The gene is 27 kb in length, containing 13 exons. 
 
2.3.3.3. CYP3A5 rs776746G>A SNP Characterisation 
Figure 2.4 shows the position of SNPs genotyped for in CYP3A5. To genotype for CYP3A5*3 (rs776746 
A) allele, a 293 bp fragment was amplified under the following conditions (adapted from Van Schaik 
et al. (175) with modifications): initial denaturation at 94°C for 3 min, followed by 30 cycles at 94°C 
for 30 s, 51°C for 30 s, and 72°C for 30 s; and a final extension step at 72°C for 10 min. The Mycycler™ 
Thermal Cycler (Bio-Rad, Hercules, USA) was used for the PCR reaction. The amplified fragments were 
digested with the SspI restriction enzyme (Thermo Fisher Scientific, Wilmington, USA) incubated 
overnight at 37°C and then at 65°C for 5 min to inactivate the enzyme. The digested products were 
separated on a 4.5% nusieve gel for 120 min at 80 V, followed by 60 min at 120 V. In the presence of 
the G variant, the restriction site is abolished to yield 125 bp and 168 bp fragments; whilst for the A 
allele three fragments of 20, 125 and 148 bp were obtained. 
 
2.3.3.4. CYP3A5 rs10264272C>T SNP Characterisation 
In order to genotype for the CYP3A5*6 (rs10264272T) allele, a 495 bp fragment was amplified using 
the following using forward primer: 5ʹ-TGG AAG ATG ATT CAG ATA-3ʹ and reverse 5ʹ-GTG GGG TGT 
TGA CAG CTA AAG-3ʹ. The conditions used for PCR were adapted from Van Schaik et al. (175) and 
modified as necessary: initial denaturation at 94°C for 3 min, followed by 30 cycles of 94°C for 30 s, 
58°C for 30 s, and 72°C for 40 s; and a final extension step of 72°C for 10 min; the reaction was 
performed on a MyCycler™ Thermal Cycler (Bio-Rad, Hercules, USA). The amplified fragment was 
digested with the HpyF3I (DdeI) restriction enzyme (Thermo Fisher Scientific, Wilmington, USA) 
incubated overnight at 37°C and then at 65°C for 5 min to inactivate the enzyme. The digested 
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products were then separated on a 4.5% nusieve gel for 120 min at 80 V, followed by 60 min at 120 V. 
In the presence of the T variant, a restriction site was abolished to yield four fragments of 25, 103, 137 
and 230 bp; whilst digestion of the C variant yielded three fragments of 128, 137 and 230 bp. 
 
Sequencing was performed to confirm the genotypes identified, using the ABI Big Dye ® Terminator 
v3.1 Cycle Sequencing Kit (Life Technologies, California, USA). Sequenced products were analysed via 
capillary electrophoresis on the ABI Prism 3130 Genetic Analyzer (Life Technologies, California, USA). 
Genotypes for both the rs776746A>G and rs10264272C>T SNPs were confirmed by cycle sequencing 
and aligned to the CYP3A5 reference sequence (NCBI Reference Sequence: NC_000007.14) using 
DNAstar Lasergene® SeqMan Pro™ software (DNASTAR Inc., Madison, USA). 
 
 
Figure 2.4 Schematic diagram of CYP3A5 gene. The position of SNPs that were genotyped are 
indicated with arrows. The gene is 32 kb in length, containing 13 exons. 
 
2.3.4 Characterisation of variation in ABCC2 
In order to genotype ABCC2 c.1249G>A (rs2273697), PCR-RFLP was performed (Fig. 2.5). The 
genotyping conditions used were adapted from Qu et al. (161). PCR amplification was performed on 
a T100™ Thermal Cycler (Bio-Rad, Hercules, USA): initial denaturation at 94°C for 3 min, followed by 
35 cycles of 94°C for 30 s, 61°C for 30 min, and 72°C for 1 min; and a final extension step of 72°C for 5 
min. The amplified fragments were separated on a 1.5% Agarose Gel at 80 V for 90 min to confirm 
amplification, a fragment of 303 bp was expected. The amplified fragment was digested using the NcoI 
restriction enzyme (Thermo Fisher Scientific, Wilmington, USA), incubated at 37°C overnight (± 16 hrs). 
Digested products were resolved on a 4% agarose gel at 80 V for 120 min. For the G allele, fragments 





Two regions within the promoter of ABCC2 were amplified by PCR and sequenced to identify known 
and novel SNPs. Primers used for PCR and sequencing were taken from a protocol by Fujita et al. (176). 
To amplify the 214 bp region from -1632 to -1419 upstream of ABCC2 (including an known c.-1549G>A 
SNP), using the following primers, forward: 5ʹ-AAA AGT GTC TGT TCA AGT CC-3ʹ and reverse: 5ʹ-GTG 
AAT TGT ATG GAC CTT GT-3ʹ the PCR conditions were: initial denaturation at 94°C for 3 min, 94°C for 
30 s, then 35 cycles of 51°C for 30 s, 72°C for 1 min and 72°C for 5 min. To amplify the 249 bp region 
from -1157 to -908 upstream of ABCC2 (including the known c.-1019A>G SNP) the primers were as 
follows, forward: 5ʹ-GGA TAC CGC ATG GGT TC-3ʹ and reverse: 5ʹ-ACT ACA GGC ACA TGC CCA CA-3ʹ. 
PCR amplification conditions were an initial denaturation at 94°C for 3 min, 94°C for 30 s, then 35 
cycles of 60°C for 30s, 72°C for 1 min and 72°C for 5 min. The T100™ Thermal Cycler (Bio-Rad, Hercules, 
USA) was used for PCR amplification of both fragments.  
 
Sequencing was performed on the Applied Biosystems®2720 Thermal Cycler (Life Technologies, 
California, USA) as described in section 2.3.1.3 above. The sequences were assembled and aligned 




Figure 2.5 Schematic diagram of the ABCC2 gene. The gene is 69 kb long ad has 32 coding exons 
(blue boxes). Two known SNPs of interest are indicated with arrows.   
 
2.4 Measurement of Lopinavir plasma levels 
To measure the LPV plasma levels for the samples, the plasma samples were sent to the Division of 
Clinical Pharmacology, University of Cape Town for analysis. LPV concentrations were measured by 
liquid chromatography tandem mass spectrometry (LC-MS/MS). This method allows for the 
identification of proteins and peptides through providing information about the primary sequence and 




2.5 Statistical Analysis 
A chi-squared analysis was used to determine whether differences in frequency distribution between 
populations were statistically significant; a χ² statistic and p-value were obtained. LD tests were 
performed using the SHEsis online software (178). GraphPad Prism 5 was used to obtain column 
statistics (mean, lower and upper confidence interval, and standard deviation), and used for genotype 
and LPV plasma level associations. The statistical analyses conducted using this program were t-test 
to compare two groups, and One-Way Analysis of Variance (ANOVA) to compare more than two 
groups. Fisher’s Exact test was used when testing for an association between genotypes and LPV 




This project sought to evaluate the pharmacogenetics of lopinavir (LPV) by correlating 32 genetic 
variants in four genes, CYP3A4 (2 SNPs), CYP3A5 (2 SNPs), SLCO1B1 (22 SNPs) and ABCC2 (6 SNPs) with 
plasma LPV concentration. The genetic analysis involved genotyping using PCR-RFLP for the following 
SNPs: CYP3A4 rs2740574A>G; CYP3A5 rs776746A>G and rs10264272C>T; and ABCC2 rs2273697G>A. 
The rest of the SNPs were genotyped using targeted sequencing where sections of genes known to 
harbour mutations were selected for sequencing. The CYP3A4*22 allele was however evaluated using 
SNP analysis by a TaqMan genotyping assay. The study was carried out in a total of 86 patients on 
second-line ARV. Samples were limited as, at the time of sampling, there were few people who were 
on second-line containing LPV. The patient cohort comprised of 57 females, and their age ranged from 
19 to 60 years. LPV plasma concentrations were available for 64 of the 86 participant samples. Other 
clinical parameters such as CD4 count, viral load, liver enzyme levels [aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT)] were collected and formed part of the analysis. 
 
3.1. Frequency distribution of variant SNPs 
A total of 32 SNPs in the four genes were genotyped for. Three were observed to be monomorphic, 
and these are CYP3A4 rs35599367C>T; and SLCO1B1 rs4149056T>C (see Table 3.1). The SNP at 
position c.-999 of ABCC2 was not present in the annotated gene (using the PerlV5 program; NCBI 
Reference Sequence: NC_000010.11.) Most SNPs were in Hardy-Weinberg equilibrium (HWE), except 
for CYP3A5 rs776746A>G; SLCO1B1 rs4149049A>G, and rs4149053G>T. The SNPs in each gene were 
used to construct haplotypes as well as evaluate LD. Figures 3.1, 3.2 and 3.3 show the haplogroups for 
ABCC2, SLCO1B1 exon 5, and exon 6 and 7.  
 
For the four genes, CYP3A4, CYP3A5, SLCO1B1 and ABCC2, the most common alleles in each gene 
respectively were CYP3A4*1B (rs2740574G) (0.80); CYP3A5*3 (rs776746G) (0.21); SLCO1B1 rs2306283 
(c.388A>G) (0.86); and ABCC2 rs1885301 (c.-1549A>G) (0.64), while the least common were, CYP3A4 
rs35599367T (0.00), CYP3A5*6 (rs10264272T) (0.20); ABCC2 rs17222653A (0.014); and SLCO1B1 
rs4149056 (0.00) (Table 3.1). The frequencies for all the genotyped variants are presented in Table 
3.1. Genotypes for all the samples (n=86) were only available for CYP3A4*1B which was genotyped 
first. For the remaining variants, certain samples could not be genotyped because either the DNA 
sample had been finished or could not amplify at that locus. Hence, the differences observed in the 




When comparing the distribution of allelic variants in our cohort to that in other populations, Table 
3.1 also shows that, for the SNPs investigated, our cohort differed significantly at 19/32 loci, when 
compared to Caucasian (CEU) populations. The Chinese (CHB) populations differed with this southern 
African cohort on 5 loci. The other African population group, Yoruba (YRI) differed with this cohort 
only on one loci, while there were no significant differences in the distribution of compared SNPS with 
the Luhya in Webuye, Kenya (LWK).
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CYP3A4                
rs2740574G (*1B) 0.8 86 0.71 0.017  106.704 <0.0001* 0.767  0.118 0.7307 0.825  0.0591 0.8079 0.00  120.964 <0.0001* 
rs35599367T (*22) 0.00 84 N/A 0.052   2.695 0.1007 0.00  N/A N/A 0.00  N/A N/A 0.00  N/A N/A 
CYP3A5                
rs776746G (*3) 0.21 83 0.000031† 0.954  94.2 <0.0001* 0.159 0.44 0.5073 0.124 1.829 0.1762 0.686 38.830 <0.0001* 
rs10264272T (*6) 0.2 83 0.98 0.00 17.08 <0.0001* 0.165 0.156 0.6932 0.247 0.329 0.5664 0.00 19.049 <0.0001* 
ABCC2                
rs2273697 c.1249A 0.12 84 0.2155 0.236 3.163 0.0753 0.250 3.969 0.0464* 0.196 1.405 0.2358 0.134 0.0034 0.9536 
rs17222653 c.-1536A 0.014 73 0.9055 0.00 0.0123 0.9116 0.00 0.0136 0.9070 0.005 0.428 0.8361 0.00 0.0278 0.8676 
rs1885301 c.-1549G 0.64 74 0.5645 0.603 0.102 0.7496 0.597 0.159 0.6902 0.619 0.0148 0.9030 0.727 1.105 0.2931 
rs7910642 c.-1023A 0.16 83 0.335 0.08 1.885 0.1697 0.114 0.427 0.5136 0.186 0.0684 0.7937 0.258 2.013 0.156 
rs2804402 c.-1019G 0.31 83 0.264 0.397 1.05 0.3054 0.267 0.204 0.6515 0.304 0.0056 0.9401 0.273 0.145 0.7035 
SLCO1B1                
rs182769903 c.360-
66G 
0.006 82 0.9557 N/D N/A N/A N/D N/A N.A N/D N/A N/A N/D N/A N/A 
rs2306283 c.388G 0.86 84 0.5958 0.41 35.263 <0.0001* 0.824 0.191 0.6618 0.825 0.192 0.6609 0.794 0.938 0.3328 
rs11045818 c.411A 0.006 84 0.9562 0.213 16.478 <0.0001* 0.006 0.975 0.3233 0.00 0.423 0.5155 0.005 0.846 0.3576 
rs11045819 c.463A 0.05 84 0.6468 0.213 8.488 0.0036* 0.06 0.0015 0.9691 0.03 0.0734 0.7865 0.01 2.051 0.1521 
rs77271279 c.481+1T 0.02 84 0.8677 0.00 0.303 0.5822 0.057 0.739 0.39 0.026 0.0518 0.82 0.00 0.387 0.5338 
rs11045820 
c.481+160T 
0.006 84 0.9562 0.213 16.478 <0.0001* 0.006 0.975 0.3233 0.00 0.423 0.5155 0.005 0.846 0.3576 
rs4149044 c.481+165T 0.66 84 0.6334 0.167 0.846 0.3576 0.614 0.219 0.6398 0.546 1.984 0.1590 0.51 3.564 0.059 
rs4149045 c.481+189A 0.65 84 0.7593 0.167 39.417 <0.0001* 0.61 0.11 0.7405 0.546 1.611 0.2043 0.51 3.06 0.0802 
rs4149046 c.481+191A 0.02 84 0.8231 0.494 47.337 <0.0001* 0.028 0.0241 0.8765 0.021 0.229 0.6325 0.21 13.069 0.0003* 
rs189925961 
c.481+242T 
0.006 84 0.9562 N/D N/A N/A N/D N/A N/A N/D N/A N/A N/D N/A N/A 
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rs4149048 c.481+520G 0.63 82 0.4339 0.167 36.062 <0.0001* 0.614 0.0032 0.9548 0.55 0.968 0.3251 0.51 2.138 0.1437 
rs4149049 c.482-823G 0.22 81 0.0006† 0.029 12.64 0.0004* 0.142 1.254 0.2629 0.18 0.228 0.6328 0.28 0.511 0.4749 
rs4149050 c.482-522C 0.66 80 0.4433 0.19 36.006 <0.0001* 0.619 0.153 0.6593 0.557 1.537 0.2150 0.515 3.213 0.073 
rs4149051 c.482-453G 0.66 80 0.4433 0.19 36.006 <0.0001* 0.619 0.153 0.6593 0.567 1.226 0.2682 0.515 3.213 0.073 
rs4149052 c.482-451G 0.66 80 0.4433 0.19 36.006 <0.0001* 0.619 0.153 0.6593 0.567 1.226 0.2682 0.515 3.213 0.073 
rs4149053 c.482-375T 0.56 79 0.0405 0.19 22.856 <0.0001* 0.557 0.0137 0.9068 0.5 0.411 0.5214 0.515 0.197 0.6575 
rs4149054 c.482-331A 0.54 80 0.0501 0.19 20.725 <0.0001* 0.54 0.024 0.8768 0.49 0.261 0.6092 0.52 0.0325 0.8569 
rs141555703 c.482-
272A 
0.08 79 0.4255 N/D N/A N/A N/D N/A N/A N/D N/A N/A N/D N/A N/A 
rs67496683 c.482-
120_482-115del 
0.62 81 0.0961 N/D N/A N/A N/D N/A N/A N/D N/A N/A N/D N/A N/A 
rs4149056 c.521C 0.00 81 N/A 0.14 10.604 0.0011* 0.011 0.0054 0.9414 0.021 0.365 0.5457 0.149 11.214 0.0008* 
rs4149057 c.571C 0.09 81 0.5782 0.69 60.409 <0.0001* 0.153 1.024 0.3115 0.052 0.487 0.4853 0.206 3.728 0.0535 
rs2291075 c.597T 0.59 81 0.2396 0.402 5.203 0.0225* 0.614 0.026 0.8720 0.521 0.594 0.4410 0.521 0.594 0.441 
Χ2: Chi-squared statistic for comparison of allele frequencies obtained in study compared to selected populations.  
†: Frequencies not in HWE 
*: p<0.05 (frequency of allele in population is significantly different to that obtained in the study) 
Na: Not all samples were successfully genotyped for each of the SNPs due to difficulties or lack of adequate amounts 
HWE: Hardy-Weinberg equilibrium 
CEU: Utah residents with N & W European ancestry from the CEPH collection 
YRI: Yoruba in Ibadan, Nigeria 
LWK: Luhya in Webuye, Kenya 
CHB: Han Chinese in Beijing, China 
N/D: No data 





3.2. Linkage Disequilibrium Analysis 
Haplotypes were calculated for the SNPS that were genotyped in the same gene. Figures 3.1, 3.2 and 
3.3 show the LD plots for the two genes, ABCC2 and SLCO1B1. The SNPs in ABCC2 had a very high D’ 
and the low r2 and this was mainly due to differences in allele frequencies (Fig. 3.1). Figure 3.2 presents 
the LD plots for SLCO1B1 exon 5 to 7 and surrounding introns. It appears, the intronic region starting 
from position c.481 (i.e. rs77271279 c.481+1T), is an unstable region thus, so many SNPs. Most of 
these present with very high D’ but also have low r2 as shown for ABCC2 (see Fig. 3.2).   
 
 
Figure 3.1 Linkage Disequilibrium plot for c.-1563G>A (rs17222653); c.-1549A>G (rs1885301); c.-











3.3. Effects of genetic variants on Lopinavir therapeutic levels 
From the 85 patient samples which were genotyped, plasma LPV levels were available for 74. Ten 
samples out the 74 had LPV levels below the lower limit of quantification (BLQ) of 0.0195 µg/mL. 
Samples with BLQ values were excluded from further genotype-plasma LPV level association analysis 
and were excluded from determination of the distribution of LPV concentrations (Fig. 3.3 A and B). 
The excluded patient samples were not limited to either one of the populations. Plasma LPV levels 
were thus available for 64 patient samples. The mean of LPV levels was 9.401 µg/mL with a standard 
deviation of 6.760 µg/mL. The Cmin and Cmax values of 5.5 and 9.6 µg/mL, which indicate the therapeutic 
range are shown in Fig. 3.3 A. Most of the LPV levels obtained in our study fell outside the therapeutic 
range – 28% (n=18/64) were below the therapeutic range, while 39% (n=25/64) were above the 
therapeutic range. Only 33% (n=21/64) were within the therapeutic range. When samples were 
divided according to the sex of the individuals (Fig. 3.3 B), males (n=21) had a mean LPV concentration 
of 10.78 µg/mL, with a standard deviation of 7.053 µg/mL, while females (n=43) had a mean LPV 
concentration of 8.727 µg/mL, with a standard deviation of 6.591 µg/mL. There was no significant 
difference between the mean LPV concentration in males and in females (p=0.4029; Fig. 3.3 B).  
 
 
Figure 3.3 Distribution of LPV plasma concentrations. N=10 samples were omitted with LPV levels 
that were below level of quantification (<0.0195 µg/mL). A: Distribution of LPV levels in the study 
cohort; B: Gender comparison of distribution of LPV levels.  
 
One Way ANOVA and Mann-Whitney t test were performed to determining any association between 
LPV plasma levels and the different genotypes observed (Table 3.2). Only CYP3A4 rs2740574A>G 
(p=0.0479) showed a significant association with LPV plasma levels (Table 3.2 and Fig. 3.5). ABCC2 
rs7910642G>A showed a trend towards significance (P=0.072) when using an additive genetic model 
to compare the G/G genotype to the G/A and A/A genotypes. A few of the graphs have been shown 
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in this section and the remaining graphs can be found in Appendix B. Figures 3.5, 3.6 and 3.7 show a 
selection of some of the correlations between LPV concentration levels and genotypes. No association 
was found with any of the CYP3A5 rs776746A>G or rs10264272C>T genotypes and LPV levels (Fig. 3.6; 
Table 3.2). For both SNPs, analysis was also conducted using an additive genetic model. For the ABCC2 
rs2273697G>A and rs17222653 SNPs, no patients had the A/A genotype (Table 3.2; Fig. 3.7). For the 
ABCC2 rs7910642 (c.-1023G>A) SNP, the combined G/A and A/A genotypes showed a trend towards 
association with lower LPV levels (Fig. 3.8 B).  
 
The therapeutic range for LPV concentrations was taken into account to evaluate if there were 
particular genotypes that correlated with particular levels. As observed in Table 3.3, it was observed 
that the SLCO1B1 rs4149049A>G genotypes showed a significant difference in their distribution when 
comparing LPV concentrations below therapeutic range to those within the therapeutic range 
(P=0.0001). Nearly 87% (n=13/15) of the patients with either the A/G or G/G had LPV levels within the 
therapeutic range compared to only 24% (n=7/29) of the patients presenting with the A/A genotype.  
This result is also presented in Figure 3.4. SLCO1B1 rs4149050A>G, rs4149051A>G, and rs4149052A>G 
genotypes showed borderline significance also when comparing LPV concentrations below 




Table 3.2 The association of variant SNPs with plasma lopinavir levels. 
SNP Genotype N 
Mean plasma 
LPV level (± SD) 
p-value 95% CI 
CYP3A4  
rs2740574A>G A/A 2 12.91 (± 11.30) 
0.1011 
(-88.61 to 114.4) 
 A/G 22 7.287 (±4.559) (5.27 to 9.31) 
 G/G 37 11.12 (±7.246) (8.70 to 13.53) 
 A/A and A/G 24 7.756 (±5.201) 0.0479* (5.56 to 9.95) 
ABCC2 
rs7910642G>A G/G 45 10.48 (±6.822) 
0.2065 
(8.43 to 12.52) 
 G/A 16 7.589 (±6.207) (4.28 to 10.90) 
 A/A 1 6.875  N/A 
 G/A and A/A 17 7.547 (±6.013) 0.0722 (4.46 to 10.64) 
SLCO1B1 
rs2306283A>G A/A 1 N/A 
0.1198 
0 
 A/G 19 7.140 (±3.917) (5.25 to 9.028) 
 G/G 42 10.71 (±7.436) (8.39 to 13.02) 
 A/A and A/G 20 7.503 (±4.144) 0.1504 (5.56 to 9.443) 
rs4149044A>T A/A 9 9.725 (±7.492) 
0.2913 
(3.97 to 15.48) 
 A/T 31 8.942 (±7.293) (6.27 to 11.62) 
 T/T 22 10.68 (±5.557) (8.22 to 13.14) 
 A/A and A/T 40 9.118 (±7.248) 0.1296 (6.80 to 11.44) 
rs4149045G>A G/G 9 9.725 (±7.492) 
0.3895 
(3.97 to 15.48) 
 G/A 31 8.942 (±7.293) (6.27 to 11.62) 
 A/A 22 10.68 (±5.557) (8.22 to 13.14) 
 G/G and G/A 40 9.118 (±7.248) 0.1296 (6.8 to 11.44) 
rs4149057T>C T/T 52 9.876 (±7.297) 
0.3752 
(7.85 to 11.91) 
 T/C 7 6.626 (±2.111) (4.68 to 8.58) 
 C/C 1 N/A 0 
 T/C and C/C 8 6.658 (±1.956) 0.1673 (5.02 to 8.29) 
Only SNPs with p≤0.200 have been indicated in this table. See the complete table in Appendix B. LPV=lopinavir; SD=standard deviation. 
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Table 3.3 The correlation between genotypes and lopinavir levels taking into account lopinavir therapeutic range. 












rs2740574A>G        
A/A 2 (0.08) 0 1 (0.04) 3 
0.2566 0.3135 0.1565 
A/G 12 (0.48) 8 (0.4) 7 (0.26) 27 
G/G 11 (0.44) 12 (0.6) 19 (0.7) 42 
Total 25 20 27  
ABCC2 
rs7910642G>A        
G/G 14 (0.58) 16 (0.8) 21 (0.78) 51 
0.1325 0.1013 0.4339 
G/A 10 (0.42) 3 (0.15) 6 (0.22) 19 
A/A 0 1 (0.05) 0 (0) 1 
Total 24 20 27  
SLCO1B1 
rs4149045G>A        
G/G 2 (0.08) 6 (0.3) 2 (0.07) 10 
0.1938 0.1013 0.956 
G/A 11 (0.44) 9 (0.45) 13 (0.48) 33 
A/A 12 (0.48) 5 (0.25) 12 (0.44) 29 
Total 25 20 27  
rs4149048A>G        
A/A 4 (0.17) 6 (0.3) 2 (0.07) 12 
0.1470 0.1572 0.4516 
A/G 8 (0.35) 10 (0.5) 13 (0.48) 31 
G/G 11 (0.48) 4 (0.2) 12 (0.44) 27 
Total 23 20 27  
rs4149049A>G        
A/A 22 (0.92) 7 (0.35) 20 (0.77) 49 
0.00008 0.0001 0.0686 
A/G 0 (0) 10 (0.5) 5 (0.19) 15 
G/G 2 (0.08) 3 (0.15) 1 (0.04) 6 
Total 24 20 26  
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Table 3.3 continued 











SLCO1B1        
rs4149050A>G        
A/A 2 (0.09) 6 (0.3) 2 (0.08) 10 
0.0946 0.0531 0.995 
A/G 9 (0.39) 10 (0.5) 10 (0.4) 29 
G/G 12 (0.52) 4 (0.2) 13 (0.52) 29 
Total 23 20 25  
rs4149051A>G        
A/A 2 (0.09) 6 (0.3) 2 (0.08) 10 
0.0946 0.0531 0.995 
A/G 9 (0.39) 10 (0.5) 10 (0.4) 29 
G/G 12 (0.52) 4 (0.2) 13 (0.52) 29 
Total 23 20 25  
rs4149052A>G        
A/A 2 (0.09) 6 (0.3) 2 (0.08) 10 
0.0946 0.0531 0.995 
A/G 9 (0.39) 10 (0.5) 10 (0.4) 29 
G/G 12 (0.52) 4 (0.2) 13 (0.52) 29 
Total 23 20 25  
rs4149053G>T        
G/G 7 (0.32) 7 (0.35) 4 (0.16) 18 
0.2005 0.1628 0.2357 
G/T 5 (0.23) 9 (0.45) 11 (0.44) 25 
T/T 10 (0.45) 4 (0.2) 10 (0.4) 24 
Total 22 20 25  
rs4149057T>C        
T/T 19 (0.76) 16 (0.8) 23 (0.96) 58 
0.1192 0.4232 0.2332 
T/C 6 (0.24) 3 (0.15) 1 (0.04) 10 
C/C 0 (0) 1 (0.05) 0 (0) 1 
Total 25 20 24  





Figure 3.4 Association of rs4149049A>G genotypes and LPV therapeutic range. Fisher’s Exact test 















Figure 3.5 Association between LPV plasma levels and CYP3A4 rs2740574A>G genotypes. A: 
p=0.1011, Kruskal Wallis One Way ANOVA; B: *p<0.05 when using a recessive genotype model to 
compare genotypes Mann-Whitney test. 
 
 
Figure 3.6 Association between LPV plasma levels and CYP3A5 rs776746A>G genotypes. A: 
p=0.6422, Kruskal Wallis ANOVA; B: p=0.3556 when using a dominant genetic model to compare 






Figure 3.7 Association between LPV plasma levels and ABCC2 rs2273697 (c.1249G>A) genotypes 
(p=0.8663, Mann-Whitney test). 
 
 
Figure 3.8 Association between LPV plasma levels and ABCC2 rs7910642 (c.-1023G>A) genotypes (A: 






4. Discussion and Conclusion 
The treatment of HIV-infected individuals has improved through the introduction and use of combined 
highly reactive antiretroviral therapy (HAART) instead of using single-drug regimens (21, 179). 
Different levels of therapy are incorporated in the use of HAART – patients begin treatment on a first-
line regimen and then progress on to a second-line and possibly a third-line regimen if treatment 
failure is experienced. In resource-limited settings, access to treatment becomes more difficult as 
patients move from one line to the next as drugs become increasingly costly (45). Treatment failure 
can be due to viral resistance to the drug (virologic failure) which can be due to viral genotypic 
resistance to the drug, often as a result of poor adherence to treatment. Thus, it is vital to ensure that 
patients adhere to their treatment. One of the ways to improve adherence is to identify markers of 
poor response among patients.  
 
Thus, our study evaluated the pharmacogenetics of a second-line protease inhibitor, lopinavir (LPV), 
to identify genetic markers that were associated with patients presenting with either low LPV (which 
is associated with development of virus resistance) or high LPV (which may be associated with LPV-
associated side-effects. Although the sample cohort used in the study was small, the study is relevant 
due to the increasing number of HIV-infected individuals moving from first-line to second-line ARV 
therapy. It is particularly relevant in our context as most studies are conducted in Western or Asian 
populations, rather than in sub-Saharan Africa where the HIV pandemic has hit the hardest. Indeed, 
as already shown in the results, some of the genetic variants that are important in LPV response 
(c.521C>T) are rare or absent in African populations.  
 
Pharmacogenetic factors also play a role in the efficacy and disposition of ARVs in the treatment of 
HIV. For example, drug metabolising enzyme genes for which certain ARVs are known to be substrates, 
may harbour genetic variation that influences the metabolism of these drugs. Genes that may be 
involved in this include those coding for CYP2B6, CYP3A4/5, and CYP1A2 which metabolise some of 
the common ARV drugs. Other important genes encode for drug transporter proteins such as MDR1, 
MRP2, and OATP1B1. Within CYP2B6, 516G>T has been identified as a marker for variable efavirenz 
plasma concentrations in HAART patients (180-182).    
 
4.1. Frequency distribution of relevant SNPs 
Thirty-two SNPs were genotyped for in four genes which may play a role in LPV pharmacogenetics; 
namely, CYP3A4, CYP3A5, SLCO1B1, and ABCC2 (Table 3.1). The SNPs and regions of genes to be 
sequenced were selected based on their suggested effect on the protein function. In CYP3A4, both 
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CYP3A4 -392G (*1B) and the intronic CYP3A4*22 alleles have been associated with decreased protein 
expression as decreased activity. We report a high prevalence of CYP3A4*1B (0.80) in our cohort, 
which is comparable to other African populations (see YRI and LWK, in our study) but much higher 
than reported in Caucasians (0.017) and Chinese (0.00) (Table 3.1). The CYP3A4*22 allele which has 
become an important allele in drug response among Caucasian populations was not found in this 
population. Already, these differences, at the CYP3A4 loci, which is important in the metabolism of 
LPV, are a window, into the possible differences in therapeutic outcome when LPV is administered in 
different populations.  
 
CYP3A5*3 and CPY3A5*6 were selected based on their importance in affecting expression and activity 
of CYP3A5 enzyme, especially CYP3A5*3 is thought to exert its effects through the degradation of the 
mRNA due to a premature stop codon, resulting in low levels of CYP3A5. Both SNPs were observed in 
our cohort.  CYP3A5*3 was observed at a frequency of 0.21, which is significantly lower than in 
Caucasians (0.954; p<0.0001) and Asians (0.686; p<0.0001) when compared to our cohort (0.21) but 
comparable to other African populations (YRI: 0.159 and LWK: 0.124) (Table 3.1). Together with 
CYP3A4, CYP3A5 participates in the metabolism of many commonly used therapeutic drugs (114), 
thus, these observed differences between populations, are bound to present as differences in 
effectiveness of drugs that are substrates of these enzymes. However, no correlations were observed 
for CYP3A5 genotypes and plasma LPV levels in our study, possibly pointing to these enzymes playing 
a minor role in the metabolism or disposition of LPV.   
 
OATP1B1 is involved in the hepatic uptake of substrates including LPV. Studies have shown a role of 
this transporter in the disposition of LPV (79, 105, 133). Many SNPs have been reported in SLCO1B1 
which form various haplotypes. For example, SLCO1B1 rs4149056 (c.521T>C) and rs2306283 
(c.388A>G) form the haplotypes c.521C/c.388A (*5); and c.521C/c.388G (*15), which have been 
associated with decreased uptake of substrates by OATP1B1 (134). However, most studies have been 
carried out in other populations and not much on African populations. SLCO1B1 is particularly 
important in southern Africa (given that this is the region hardest hit with HIV/AIDS) because of the 
protein (OATP1B1)’s involvement in the transport of most ARVs. Thus, two genic regions which 
included these two SNPs were sequenced to identify any novel variants or other SNPs which may be 
important. The regions included exon 5 and its intron-exon junctions as well as a region encompassing 
exon 6 and 7 and their exon-intron junctions. As with CYP3A4*22, the SLCO1B1 c.521T>C was not 
observed in our cohort. Finally, in ABCC2, part of the promoter region was sequenced which included 
prior-mentioned SNPs of interest, to determine any variation which could influence ABCC2 expression. 
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Also, the ABCC2 c.1249G>A SNP was genotyped as it has been reported to be in LD with the c.-24C>T 
(rs717620) SNP. However, the c.-24C>T SNP was not genotyped for in our study because of its low 
frequency in sub-Saharan African populations (0.03-0.04) as observed in literature.   
 
Notably, the two SNPs of interest which were absent in our cohort, SLCO1B1 rs4149056T>C (c.521T>C) 
and CYP3A4 rs35599367C>T (CYP3A4*22 allele), have been reported to influence LPV 
pharmacokinetics (133) (Table 3.1). Separate studies by Elens et al. (183-185) have reported an 
association of CYP3A4*22 with greater levels of various drugs, including simvastatin (study in 
Rotterdam), cyclosporine  and taclorimus (studies in Belgium) in respective patients. The majority of 
the participants for the various studies were white, and very few black participants (between 2 and 
4%) were. On the other hand, SLCO1B1 the influence of c.521T>C on the disposition of statins has 
been investigated in European (186-188), American (European and African) (189), and Asian (190); 
and that of LPV in Brazilian (191), American  and British  cohorts (105), to name a few. The absence of 
these SNPs in Southern Africans further affirms the need for population-specific pharmacogenetic 
studies rather than accepting results reported in other populations (e.g. Caucasian) and extrapolating 
their findings to African populations. There is, in any case huge genetic diversity in African populations 
relative to non-African populations (192, 193). The observed differences in distribution of genetic 
variants as well as in their frequencies have implications for personalised medicine and highlight the 
need, at least, for population-specific if not individualised genetic testing before the prescribing of or 
adjustment of drug dosages. An example of an application of this is in the use of EFV which is largely 
metabolised by CYP2B6. Identification of individuals with the slow-metaboliser allele for the 
CYP2B6 c.516G>T SNP, 516T, allows for EFV dosing adjustments in those individuals. This allele is found 
at a higher frequency in African populations (45-47%) compared to European and Asian populations 
(21.4% and 17.4%, respectively) (194).  
 
The genetic diversity present on the African continent also means that information about a population 
in one region within (e.g. West Africa) cannot automatically be extrapolated to another region in Africa 
(e.g. Southern Africa). In our study this was only evident for the ABCC2 rs2273697 (c.1249A) allele for 
which there was a significant difference between the frequency of this allele in our cohort (0.12) and 
in the YRI population (0.25; p=0.0464). Previously, differences in CYP1A2 -163C>A allele and genotype 
frequencies have been reported between Cameroonian (in West Africa) and South African populations  
(139, 195). In addition, African American populations which have often been used as a proxy for 
African populations are admixed, mostly from West African and East African populations, and 
European populations (196). In one study, African Americans were reported to show greater diversity 
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than either of the two ancestral populations (196). However, as stated earlier, as West African 
populations may show different genotype and allele frequencies to Southern Africa populations, 
African Americans are still not a reliable proxy for all African populations. This emphasises the need 
for studies done on relevant populations and highlights the importance of this current study. 
 
4.2. Influence of genetic variation on Lopinavir disposition 
The participants involved in our study had been on treatment including LPV for at least 6 months up 
to 9 years at the time of recruitment. Participants using LPV as part of their second-line treatment had 
switched from their first-line regimen due to ART failure. The general side effects that were reported 
included diarrhoea, persistent vomiting and leg numbness. It has been reported that high efavirenz 
plasma levels are associated with CYP2B6 516G>T SNP in a cohort of Bantu-speaking South Africans 
(182); and adverse effects to nevirapine treatment have been associated with the CYP2B6 c.983T>C 
SNP (197). In our study, we sought to investigate whether similar associations can be observed for 
genes involved in the metabolism and transport of LPV. 
 
As described earlier, LPV (as a protease inhibitors) acts by binding to the HI-viral protease and 
preventing the cleavage of gag and gag-pol precursor proteins by this enzyme. The current regimens 
that include LPV are as follows: AZT+3TC + LPV/r for patients in whom TDF was used in first-line 
treatment or; TDF+3TC (or FTC) + LPV/r for patients in whom AZT was used in first-line treatment. For 
twice daily administration, the elimination half-life of LPV is about 4-6 hrs, whilst its oral clearance is 
6-7 L/h (73, 74). Common adverse effects associated with LPV use are, hepatotoxicity, dyslipidaemia, 
diarrhoea and nausea (8, 56-60). Differences in plasma LPV levels may explain variation in response to 
treatment. LPV concentrations below the Cmin of 5.5 µg/mL (i.e. the minimum therapeutic 
concentration of LPV) may indicate plasma LPV levels at which the HI-virus will not be suppressed, 
while concentrations above the Cmax of 9.6 µg/mL may lead to adverse side effects. We report on a 
significant association between CYP3A4 rs2740574A>G genotypes (p=0.0479; Fig. 3.5 B, Table 3.2) and 
plasma LPV levels. Higher LPV plasma levels were observed with the G variant when a recessive genetic 
model was used to compare the combined A/A and A/G genotypes to the G/G genotype. The 
significance of this CYP3A4*1B allele remains contentious (138, 139, 141).  The role of this allele in 
CYP3A4 expression and activity and in drug pharmacogenetics remains the subject of debate (112, 
138), as discussed in the introduction. Regarding its role in LPV pharmacogenetics specifically, a pilot 
study in 20 Caucasian HIV-infected individuals undergoing LPV/r monotherapy identified two patients 
with the CYP3A4*1B allele, one who had virological rebound (>40 copies/mL of the virus) and the 
other low plasma LPV levels (1.748 µg/mL) (198). However, this was a small cohort of individuals as 
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their study was a pilot study. There is a need for more studies to be carried out to determine the role 
CYP3A4 variation in LPV levels and HI-viral suppression in HIV/AIDS patients, especially in sub-Saharan 
Africa. 
 
An association was observed with the SLCO1B1 rs4149049A>G SNP and LPV levels (Fig. 3.4; Table 3.3). 
This SNP is found in intron 5 of the gene. Although the SNP has been observed in other populations 
(199), no contribution to the pharmacokinetics of LPV or other drugs transported by OATP1B1 has 
been reported on. 
 
4.3. Limitations of the study 
One of the main limitations of our study was the small sample size. At the time of recruitment, few 
patients were on a regimen with LPV as the number of individuals on second-line therapy will generally 
be lower than that of individuals on first-line therapy. The small sample size may explain the allele 
frequencies which were not in HWE: CYP3A5 rs776746A>G; SLCO1B1 rs4149049A>G, and 
rs4149053G>T.  
 
Although two different methods were used for DNA isolation (see section 2.2.1 and section 2.2.2), we 
do not think this could have accounted for the differences observed in amplification success of 
different SNPs because all the DNA was measured using a spectrophotometer to evaluate 
concentrations and electrophoresed on agarose gel to evaluate integrity and no differences have been 
observed between the two methods. We do suspect that possibly, subsequent degradation of DNA 
may have played a role in the observed failures in amplification. 
 
Other genes which play or may play a role in LPV pharmacogenetics were not included in the study; 
these include ABCB1 (or MDR1, the multidrug resistance transporter gene which encodes p-
glycoprotein) and the ORM genes which code for the α1-acid glycoprotein (AGP). P-glycoprotein has 
been shown to be a transporter of LPV (71). Studies of the association between ABCB1 and LPV 
pharmacokinetics have been conducted in European children (108, 200). Bellusci et al. (200) reported 
an association with the ABCB1 1236C>T SNP and low LPV levels. This gene may be relevant in this 
African population. 
 
Sequencing for SLCO1B1 and ABCC2 was only carried out on short sections of the genes which may be 
mutational hotspots. Therefore, SNPs outside of these regions which may have been relevant were 
not included, such as SLCO1B1 rs4149032 which has been reported to be highly prevalent in a South 
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African cohort of black African Xhosa-speaking and mixed ancestry individuals (201). This SNP is 
located in intron 2, and hence was not covered by our sequencing of exons 5 to 7 including their intron-
exon junctions. Sequencing in ABCC2 was only conducted in parts of the promoter region. 
As this was an MSc project, time was a major limiting factor and prevented us from genotyping other 
SNPs within the selected genes, or other genes of interest. 
 
As complete data was not available for all of the patients, such as CD4 count and viral load, the possible 
reasons for some of the patient having LPV levels below the limit of detection could include poor 
adherence to drug treatment (see section 3.3). However, there was no correlation with increased viral 
load. 
 
4.4. Recommendations for future studies 
With a larger sample size, a future study of this nature could further investigate the differences in the 
pharmacogenetics of LPV within sub-populations. The Malawian and South African cohorts in this 
study were investigated as one group and not stratified according to ethnicities. 
 
As knowledge and understanding of the pharmacogenetics of LPV grows including the proteins which 
influence its disposition (the pharmacokinetics) and the proteins which are influenced by LPV (the 
pharmacodynamics), the selection of genes can be either narrowed down or expanded to those which 
are most relevant across all populations.  
 
Regions and SNPs selected for genotyping were selected based on available literature. However, as 
knowledge about genetic variation African populations, especially, is constantly being added to the 
sequencing of other regions in the genes chosen for our study may allow for a greater understanding 
of their role, if any, in the pharmacogenetics of LPV. 
 
The focus of our study was LPV, but as LPV is boosted with RTV, it may be worthwhile to investigate 
the pharmacogenetics of RTV and how (if any) they may be associated with the pharmacogenetics of 
LPV. RTV concentrations were not measured in our study. 
 
4.5. Conclusion 
In our study in which we sought to identify genes, and particular SNPs in those genes which may be 
associated with the pharmacogenetics of LPV, two variants were identified which showed a significant 
association. These are CYP3A4*1B (c.-392G) found in the promoter region of CYP3A4, and SLCO1B1 
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rs4149049A>G, an intronic SNP. These results need to be followed up in a cohort with an appropriate 
sample size. Our study further highlights the need to genetically characterise as many African 
population group in order to realise the dream of personalised medicine.  
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Appendix A: Solutions 
I. 1 M Tris-HCl 
121.1 g Tris 
1 L dH2O 
Autoclave 
 
II. Sucrose Triton X-100 Lysis Buffer 
For 1 L, add: 
10 mL 1 M Tris-HCl (pH 8.0)  
5 mL 1 M MgCl2  
10 mL Triton X-100 
109.5 g (add just before use) 
Make solution up to 1 L with dH2O 
Autoclave and keep at 4°C 
 
III. T20E5 
20 ml 1M Tris-HCl 
10 ml 0.5M EDTA (pH 8.0) 
Make up to 1 L with dH2O and autoclave 
 
IV. 10X TBE Buffer 
108 g Tris 
55 g Boric acid 
7.44 g EDTA 




Appendix B: Additional Graphs and Tables 
 
Table 6.1 The Association of variant SNPs with Plasma Lopinavir Levels (all SNPs included; refer to Table 3.2). 
SNP Genotype N 
Mean Lopinavir 
level 
p-value Lower 95% CI Upper 95% CI Std Dev 
CYP3A4  
rs2740574A>G A/A 2 12.91 0.1011 -88.61 114.4 11.30 
 A/G 22 7.287  5.266 9.309 4.559 
 G/G 37 11.12  8.700 13.53 7.246 
 A/A and A/G 24 7.756 0.0479* 5.560 9.952 5.201 
CYP3A5 
rs776746A>G A/A 39 10.14 0.6422 8.215 12.07 5.944 
 A/G 15 9.533  4.453 14.61 9.172 
 G/G 7 7.759  2.842 12.68 5.317 
 A/G and G/G 22 8.968 0.3556 5.397 12.54 8.055 
rs10264272C>T C/C 39 9.485 0.3619 7.216 11.75 6.999 
 C/T 21 10.39  7.464 13.31 6.427 
 T/T 1 N/A  N/A N/A 0 
 C/T and T/T 22 10.13 0.5184 7.300 12.96 6.387 
ABCC2 
rs2273697G>A G/G 48 9.775 0.8663 7.758 11.79 6.947 
 G/A 14 9.320  5.878 12.76 5.960 
rs17222653G>A G/G 52 10.29 0.2078 8.389 12.20 6.843 
 G/A 2 3.968  -41.04 48.98 5.010 
rs1885301A>G A/A 9 12.03 0.7546 4.083 19.97 10.33 
 A/G 24 9.895  7.321 12.47 6.096 
 G/G 21 9.405  6.642 12.17 6.070 
80 
 
 A/A and A/G 33 10.48 0.8540 7.862 13.09 7.371 
rs7910642G>A G/G 45 10.48 0.2065 8.426 12.52 6.822 
 G/A 16 7.589  4.282 10.90 6.207 
 A/A 1 6.875    0 
 G/A and A/A 17 7.547 0.0722 4.456 10.64 6.013 
rs2804402A>G A/A 29 9.222 0.6228 7.107 11.34 5.559 
 A/G 25 9.178  6.586 11.77 6.280 
 G/G 8 12.85  3.760 21.94 10.87 
 A/G and G/G 33 10.07 0.6516 7.368 12.77 7.616 
SLCO1B1 
rs2306283A>G A/A 1 N/A 0.1198 0 0 0 
 A/G 19 7.140  5.252 9.028 3.917 
 G/G 42 10.71  8.388 13.02 7.436 
 A/A and A/G 20 7.503 0.1504 5.564 9.443 4.144 
rs11045819C>A C/C 57 9.826 0.3388 8.063 11.59 6.644 
 C/A 5 7.922  -1.762 17.61 7.800 
rs77271279G>T G/G 59 9.598 0.4407 7.830 11.37 6.784 
 G/T 3 11.14  -2.018 24.30 5.298 
rs4149044A>T A/A 9 9.725 0.2913 3.966 15.48 7.492 
 A/T 31 8.942  6.267 11.62 7.293 
 T/T 22 10.68  8.216 13.14 5.557 
 A/A and A/T 40 9.118 0.1296 6.800 11.44 7.248 
rs4149045G>A G/G 9 9.725 0.3895 3.966 15.48 7.492 
 G/A 31 8.942  6.267 11.62 7.293 
 A/A 22 10.68  8.216 13.14 5.557 
 G/G and G/A 40 9.118 0.1296 6.800 11.44 7.248 
rs4149046G>A G/G 58 9.830 0.4307 8.023 11.64 6.873 
 G/A 4 7.380  3.614 11.15 2.367 
rs4149048A>G A/A 10 9.035 0.2352 3.746 14.32 7.393 
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 A/G 30 9.374  6.688 12.06 7.192 
 G/G 22 12.11  8.551 15.67 8.025 
rs4149049A>G A/A 39 10.15 0.8902 7.749 12.55 7.402 
 A/G 16 8.751  6.856 10.65 3.556 
 G/G 5 10.75  -0.7851 22.28 9.287 
 A/G and G/G 21 9.226 0.6419 6.839 11.61 5.243 
rs4149050T>C T/T 9 9.725 0.3662 3.966 15.48 7.492 
 T/C 27 9.339  6.367 12.31 7.511 
 C/C 22 10.62  8.089 13.14 5.699 
rs4149051A>G A/A 9 9.725 0.3662 3.966 15.48 7.492 
 A/G 27 9.339  6.367 12.31 7.511 
 G/G 22 10.62  8.089 13.14 5.699 
rs4149052A>G A/A 9 9.725 0.3662 3.966 15.48 7.492 
 A/G 27 9.339  6.367 12.31 7.511 
 G/G 22 10.62  8.089 13.14 5.699 
rs4149053G>T G/G 16 8.199 0.3746 4.707 11.69 6.554 
 G/T 23 10.69  7.428 13.96 7.549 
 T/T 19 10.32  7.411 13.23 6.035 
rs4149054G>A G/G 17 9.988 0.4217 4.986 14.99 9.728 
 G/A 22 9.080  7.022 11.14 4.641 
 A/A 19 10.72  7.881 13.56 5.886 
rs141555703G>A G/G 50 9.642 0.6528 7.704 11.58 6.818 
 G/A 7 11.27  4.536 18.01 7.285 
rs67496683TACTTG>del TACTTG/TACTTG 12 9.453 0.6828 4.975 13.89 7.019 
 TACTTG/del 26 9.318  6.379 12.26 7.278 
 del/del 21 10.51  7.718 13.30 6.130 
rs4149057T>C T/T 52 9.876 0.3752 7.845 11.91 7.297 
 T/C 7 6.626  4.675 8.578 2.111 
 C/C 1 N/A  0 0 0 
82 
 
 T/C and C/C 8 6.658 0.1673 5.022 8.293 1.956 
rs2291075C>T C/C 13 8.817 0.5891 4.658 12.98 6.884 
 C/T 25 9.333  6.242 12.42 7.488 
 T/T 21 10.42  7.569 13.27 6.266 





Table 6.2 Association of genotypes with Lopinavir therapeutic range (all SNPs included; refer to Table 3.3) 













rs2740574A>G        
A/A 2 (0.08) 0 1 (0.04) 3 
0.2566 0.3135 0.1565 
A/G 12 (0.48) 8 (0.4) 7 (0.26) 27 
G/G 11 (0.44) 12 (0.6) 19 (0.7) 42 
Total 25 20 27  
CYP3A5 
rs776746A>G        
A/A 14 (0.56) 16 (0.76) 17 (0.68) 47 
0.4930 0.3166 0.3042 
A/G 5 (0.2) 3 (0.14) 6 (0.24) 14 
G/G 6 (0.24) 2 (0.1) 2 (0.08) 10 
Total 25 21 25  
rs10264272C>T        
C/C 19 (0.76) 11 (0.58) 17 (0.63) 47 
0.2848 0.2165 0.2592 
C/T 5 (0.2) 8 (0.42) 10 (0.37) 23 
T/T 1 (0.04) 0 0 1 
Total 25 19 27  
ABCC2 
rs2273697G>A        
G/G 19 (0.79) 15 (0.75) 22 (0.81) 56 
0.9334 1.00 0.7230 G/A 5 (0.21) 5 (0.25) 5 (0.19) 15 
Total 24 20 27  
rs7910642G>A        
G/G 14 (0.58) 16 (0.8) 21 (0.78) 51 
0.1325 0.1013 0.4339 
G/A 10 (0.42) 3 (0.15) 6 (0.22) 19 
A/A 0 1 (0.05) 0 (0) 1 
Total 24 20 27  
rs2804402A>G        
84 
A/A 14 (0.58) 11 (0.55) 11 (0.41) 36 
0.5358 0.7483 0.2165 
A/G 9 (0.38) 7 (0.35) 11 (0.41) 27 
G/G 1 (0.04) 2 (0.1) 5 (0.19) 8 
Total 24 20 27 
rs17222653G>A 
G/G 18 (0.95) 18 (0.95) 23 (1) 59 
0.5224 1.00 0.4524 G/A 1 (0.05) 1 (0.05) 0 (0) 2 
Total 19 19 23 
rs1885301A>G 
A/A 1 (0.05) 4 (0.26) 4 (0.17) 9 
0.5519 0.3517 0.3214 
A/G 8 (0.42) 7 (0.37) 12 (0.5) 27 
G/G 10 (0.53) 8 (0.42) 8 (0.33) 26 
Total 19 19 24 
SLCO1B1 
rs2306283A>G 
A/A 0 (0) 0 (0) 1 (0.04) 1 
0.7286 0.5151 0.6219 
A/G 6 (0.24) 7 (0.35) 6 (0.22) 19 
G/G 19 (0.76) 13 (0.65) 20 (0.74) 52 
Total 25 20 27 
rs11045819C>A 
C/C 22 (0.88) 18 (0.9) 26 (0.96) 66 
0.5673 1.00 0.5671 C/A 3 (0.12) 2 (0.1) 1 (0.04) 6 
Total 25 20 27 
rs77271279G>T 
G/G 24 (0.92) 20 (1) 25 (0.92) 69 
0.7736 0.2507 0.5005 G/T 1 (0.08) 0 (0) 2 (0.08) 3 
Total 25 20 27 
rs4149044A>T 
A/A 4 (0.16) 6 (0.3) 2 (0.07) 12 
0.2914 0.3379 0.5975 
A/T 10 (0.4) 9 (0.45) 13 (0.48) 32 
T/T 11 (0.44) 5 (0.25) 12 (0.44) 28 
Total 25 20 27 
rs4149045G>A 
G/G 2 (0.08) 6 (0.3) 2 (0.07) 10 
0.1938 0.1013 0.956 
G/A 11 (0.44) 9 (0.45) 13 (0.48) 33 
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A/A 12 (0.48) 5 (0.25) 12 (0.44) 29 
Total 25 20 27  
rs4149046G>A        
G/G 24 (0.96) 18 (0.9) 26 (0.96) 68 
0.6719 0.5772 0.5671 G/A 1 (0.04) 2 (0.1) 1 (0.04) 4 
Total 25 20 27  
rs4149048A>G        
A/A 4 (0.17) 6 (0.3) 2 (0.07) 12 
0.1470 0.1572 0.4516 
A/G 8 (0.35) 10 (0.5) 13 (0.48) 31 
G/G 11 (0.48) 4 (0.2) 12 (0.44) 27 
Total 23 20 27  
rs4149049A>G        
A/A 22 (0.92) 7 (0.35) 20 (0.77) 49 
0.000076 0.0001 0.0686 
A/G 0 (0) 10 (0.5) 5 (0.19) 15 
G/G 2 (0.08) 3 (0.15) 1 (0.04) 6 
Total 24 20 26  
rs4149050A>G        
A/A 2 (0.09) 6 (0.3) 2 (0.08) 10 
0.0946 0.0531 0.995 
A/G 9 (0.39) 10 (0.5) 10 (0.4) 29 
G/G 12 (0.52) 4 (0.2) 13 (0.52) 29 
Total 23 20 25  
rs4149051A>G        
A/A 2 (0.09) 6 (0.3) 2 (0.08) 10 
0.0946 0.0531 0.995 
A/G 9 (0.39) 10 (0.5) 10 (0.4) 29 
G/G 12 (0.52) 4 (0.2) 13 (0.52) 29 
Total 23 20 25  
rs4149052A>G        
A/A 2 (0.09) 6 (0.3) 2 (0.08) 10 
0.0946 0.0531 0.995 
A/G 9 (0.39) 10 (0.5) 10 (0.4) 29 
G/G 12 (0.52) 4 (0.2) 13 (0.52) 29 
Total 23 20 25  
rs4149053G>T        
G/G 7 (0.32) 7 (0.35) 4 (0.16) 18 
0.2005 0.1628 0.2357 G/T 5 (0.23) 9 (0.45) 11 (0.44) 25 
T/T 10 (0.45) 4 (0.2) 10 (0.4) 24 
86 
Total 22 20 25 
rs4149054G>A 
G/G 7 (0.3) 7 (0.35) 5 (0.25) 19 
0.5288 0.5516 0.6771 
G/A 8 (0.35) 9 (0.45) 9 (0.36) 26 
A/A 8 (0.35) 4 (0.2) 11 (0.44) 23 
Total 23 20 25 
rs141555703G>A 
G/G 18 (0.78) 17 (0.85) 21 (0.875) 56 
0.7112 0.7041 1.00 G/A 5 (0.22) 3 (0.15) 3 (0.125) 11 
Total 23 20 24 
rs67496683TACTTG>- 
TACTTG/TACTTG 5 (0.21) 5 (0.25) 4 (0.16) 14 
0.8818 0.7672 0.7371 
TACTTG/- 8 (0.33) 8 (0.4) 11 (0.44) 27 
-/- 11 (0.46) 7 (0.35) 10 (0.4) 28 
Total 24 20 25 
rs4149057T>C 
T/T 19 (0.76) 16 (0.8) 23 (0.96) 58 
0.1192 0.4232 0.2332 
T/C 6 (0.24) 3 (0.15) 1 (0.04) 10 
C/C 0 (0) 1 (0.05) 0 (0) 1 
Total 25 20 24 
rs2291075C>T 
C/C 5 (0.2) 6 (0.29) 3 (0.13) 14 
0.8004 0.7906 0.7711 
C/T 11 (0.44) 8 (0.38) 10 (0.43) 29 
T/T 9 (0.36) 7 (0.33) 10 (0.33) 26 
Total 25 21 23 
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Figure 6.1 Distribution of lopinavir plasma concentrations. Samples with BLQ levels (<0.0195 µg/mL) 
have been included. 
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V. CYP3A4
Figure 6.2 CYP3A4*1B genotypes vs lopinavir levels. A: with BLQ samples (p-value: 0.1461, Kruskal 
Wallis One Way ANOVA); B: Recessive model with BLQ samples (p-value: 0.0511, Mann-Whitney test); 
C: without BLQ samples (p-value: 0.1011, Kruskal Wallis One Way ANOVA); D: Recessive model without 
BLQ samples (p-value: 0.0479, Mann-Whitney test). 
89 
Figure 6.3 Log of CYP3A4 rs2740574A>G (*1B) genotypes vs lopinavir levels without BLQ samples. 




Figure 6.4 CYP3A5 rs776746A>G (*3) genotypes vs lopinavir levels. A: with BLQ samples (p-value: 
0.3892, Kruskal Wallis ANOVA); B: Dominant model with BLQ samples (p-value: 0.6042, Mann-Whitney 
test); C: without BLQ samples (p-value: 0.6422, Kruskal Wallis ANOVA); D: Dominant model without 
BLQ samples (p-value: 0.3556, Mann-Whitney test). 
91 
Figure 6.5 CYP3A5 rs10264272C>T (*6) genotypes vs lopinavir levels. A: with BLQ samples (p-value: 
0.3428, Kruskal Wallis ANOVA); B: Dominant model with BLQ samples (p-value: 0.2628, Mann-Whitney 
test); C: without BLQ samples (p-value: 0.3619, Kruskal Wallis ANOVA); D: Dominant model without 





Figure 6.6 ABCC2 rs2273697 (c.1249G>A) genotypes vs lopinavir levels. A: with BLQ samples (p-value: 
0.9013, Mann-Whitney test); B: without BLQ levels (p-value: 0.8663, Mann-Whitney test) 
 
 
Figure 6.7 ABCC2 rs17222653 (c.-1536G>A) genotypes vs lopinavir levels. A: with BLQ levels (p-value: 





Figure 6.8 ABCC2 rs1885301 (c.-1549A>G) genotypes vs lopinavir levels. A: with BLQ levels (p-value: 
0.3254, Kruskal-Wallis One Way ANOVA); B: Additive recessive model with BLQ levels (p-value: 0.5799, 
Mann-Whitney test); C: without BLQ levels (p-value: 0.7546, Kruskal-Wallis One Way ANOVA); D: 
Additive recessive model without BLQ levels (p-value: 0.854, Mann-Whitney test). 
94 
Figure 6.9 ABCC2 rs7910642 (c.-1023G>A) genotypes vs lopinavir levels. A: with BLQ levels (p-value: 
0.2523, Kruskal-Wallis One Way ANOVA); B: Dominant model with BLQ levels (p-value: 0.1001, Mann-
Whitney test); C: without BLQ levels (p-value: 0.2065, Kruskal-Wallis One Way ANOVA); D: Dominant 
model without BLQ levels (p-value: 0.0722, Mann-Whitney test). 
95 
Figure 6.10 ABCC2 rs2804402 (c.-1019A>G) genotypes vs lopinavir levels. A: with BLQ levels (p-value: 
0.2207, Kruskal-Wallis One Way ANOVA); B Dominant model with BLQ levels (p-value: 0.1725, Mann-
Whitney test); C: without BLQ levels (p-value: 0.6228, Kruskal-Wallis test); D: Dominant model without 
BLQ levels (p-value: 0.6516, Mann-Whitney test). 
96 
VIII. SLCO1B1
Figure 6.11 SLCO1B1 rs2306283 (c.388A>G) genotypes vs lopinavir levels. A: with BLQ samples (p-
value: 0.3864, Kruskal-Wallis One Way ANOVA); B: Recessive model with BLQ samples (p-value: 
0.7423, Mann-Whitney test); C: without BLQ samples (p-value: 0.1198, Kruskal-Wallis One Way 




Figure 6.12 SLCO1B1 rs11045819 (c.463C>A) genotypes vs lopinavir levels. A: with BLQ samples (p-
value: 0.3803, Mann-Whitney test); B: without BLQ samples (p-value: 0.3388, Mann-Whitney test). 
 
 
Figure 6.13 SLCO1B1 rs77271279 (c.481+1G>T) genotypes vs lopinavir levels. A: with BLQ samples (p-










Figure 6.14 SLCO1B1 rs4149044 c.481+165A>T genotypes vs lopinavir levels. A: with BLQ samples (p-
value: 0.9250, Kruskal-Wallis One Way ANOVA); B: Recessive model with BLQ samples (p-value: 
0.6974, Mann-Whitney test); C: without BLQ samples (p-value: 0.2913, Kruskal-Wallis One Way 
ANOVA); D: Recessive model without BLQ samples (p-value: 0.1296, Mann-Whitney test). 
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Figure 6.15 SLCO1B1 rs4149045 (c.481+189G>A) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.9984, Kruskal-Wallis One Way ANOVA); B: Recessive model with BLQ samples (p-value: 
0.9725, Mann-Whitney test); C: without BLQ samples (p-value: 0.3895, Kruskal-Wallis One Way 
ANOVA); D: Recessive model without BLQ samples (p-value: 0.1296, Mann-Whitney test). 
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Figure 6.16 SLCO1B1 rs4149046 (c.481+191G>A) genotypes vs lopinavir levels A: with BLQ samples 
(p-value: 0.8535, Mann-Whitney test); B: without BLQ samples (p-value: 0.4307, Mann-Whitney test). 
Figure 6.17 SLCO1B1 rs4149048 (c.481+520A>G) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.7042, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 0.2352, Kruskal-
Wallis One Way ANOVA). 
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Figure 6.18 SLCO1B1 rs4149049 (c.482-823A>G) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.5294, Kruskal-Wallis One Way ANOVA); B: Dominant model without BLQ samples (p-value: 
0.8608, Mann-Whitney test); C: without BLQ samples (p-value: 0.8902, Kruskal-Wallis One Way 
ANOVA); D: Dominant model without BLQ samples (p-value: 0.6419, Mann-Whitney test). 
Figure 6.19 SLCO1B1 rs4149050 (c.482-522T>C) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.9873, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 0.3662, Kruskal-
Wallis One Way ANOVA). 
Figure 6.20 SLCO1B1 rs4149051 (c.482-453A>G) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.9873, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 0.3662, Kruskal-
Wallis One Way ANOVA). 
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Figure 6.21 SLCO1B1 rs4149052 (c.482-451A>G) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.9873, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 0.3662, Kruskal-
Wallis One Way ANOVA). 
Figure 6.22 SLCO1B1 rs4149053 (c.482-375G>T) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.51, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 0.3746, Kruskal-
Wallis One Way ANOVA). 
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Figure 6.23 SLCO1B1 rs4149054 (c.482-331G>A) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.7712, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 0.4217, Kruskal-
Wallis One Way ANOVA). 
Figure 6.24 SLCO1B1 rs141555703 (c.482-272G>A) genotypes vs lopinavir levels. A: with BLQ samples 
(p-value: 0.3131, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 0.6528, Kruskal-
Wallis One Way ANOVA). 
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Figure 6.25 SLCO1B1 rs67496683 (c.482-120_482-115TACTTGdel) genotypes vs lopinavir levels. A: 
with BLQ samples (p-value: 0.9469, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 
0.6828, Kruskal-Wallis One Way ANOVA). 
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Figure 6.26 SLCO1B1 rs4149057 (c.571T>C) genotypes vs lopinavir levels. A: with BLQ samples (p-
value: 0.1415, Kruskal-Wallis One Way ANOVA); B: Dominant model with BLQ samples (p-value: 
0.0569, Mann-Whitney test); C: without BLQ samples (p-value: 0.3752, Kruskal-Wallis One Way 
ANOVA); D: Dominant model without BLQ samples (p-value: 0.1673, Mann-Whitney test). 
Figure 6.27 SLCO1B1 rs2291075 (c.597C>T) genotypes vs lopinavir levels. A: with BLQ samples (p-
value: 0.6863, Kruskal-Wallis One Way ANOVA); B: without BLQ samples (p-value: 0.5891, Kruskal-
Wallis One Way ANOVA). 
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Appendix C: Genotyping Results 
Figure 6.28 PCR-RFLP for genotyping of CYP3A4 rs2740574A>G, CYP3A5 rs776746A>G and CYP3A5 
rs10264272C>T. A: CYP3A4 rs2740574A>G - Generuler 500 bp plus DNA ladder was used (MWM), 
lanes 1 to 3 represent samples with different genotypes (A/G; G/G; and A/A respectively); and lane 4 
contained undigested PCR product. B: CYP3A5 rs776746A>G - Lanes 1 to 3 represent samples with 
A/A, A/G and G/G genotypes respectively, lane 4 contained undigested PCR product. C: CYP3A5 
rs10264272C>T – Molecular Weight Marker V (MWM V) was used; lane 1 contains undigested PCR 
product; and in lanes 2 to 5 are samples with genotypes C/C, C/T, C/T and T/T. 
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Figure 6.29 PCR-RFLP for ABCC2 rs2273697 (c.1249G>A). A 500 bp plus DNA ladder was used (MWM); 
in lanes 1 to 4, 7 and 8 are samples with G/G genotype; and in lane 5 and 6 are samples with A/G 
genotype. Lane 9 contained undigested PCR product. 
Figure 6.30 TaqMan assay results for CYP3A4 rs35599367C>T. Blue represents the 6-FAM label for 
the T allele; Green represents the VIC (HEX) label for the C allele. A heterozygote sample from a 
separate population was included as a positive control. 
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Figure 6.31 Sequencing results for ABCC2 rs2804402 (c-1019A>G) and rs7910642 (c.-1023G>A). 
Figure 6.32 Sequencing results for ABCC2 rs17222653 (c-1563G>A) and rs1885301 (c.-1549A>G). The 
inverted trace diagram is shown. 
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Figure 6.33 Sample of sequencing results for SLCO1B1 exon 5 showing a few SNPs which were 
identified. 
Figure 6.34 Sample of sequencing results for SLCO1B1 exon 6 to 7 showing a few SNPs which were 
identified. 
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